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Summary 
The purpose of this report is to give an analysis of the effectiveness of 
HBOT in patients after stroke. This can be acbieved by illustrate the main 
pathophysiologic reactions, including inflammatory a reparatory 
mechanisms that all brain cells undergo during ischemie brain attack. The 
fundamentals of stroke where reviewed with the aim of achieving a clear 
view on the subject. Hence tbe recognition of therapeutic specificity that 
hyperbaric oxygen therapy (HBOn offers. We also took a closer look on 
the basics of HBO, its history, physiological aspects, indications, the 
principles that accompany it. An analysis of methods, results, and 
conclusions of a literature review on the use of this therapy (HBOn to treat 
manifestations of stroke in humans is assessed. 
Key words: Hyperoxygenation, adjuvant therapy, HBOT, therapeutic 
hyperbaric medicine, Acute Ischemie stroke, Neuronal cells, Non-neuronal 
cells. 
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INTRODUCTION 
Hyperbaric Medicine is the use of barometric pressure for delivering 
increased concentrations of oxygen dissolved in plasma to body tissues. 
Hyperbaric oxygen therapy (HBO) is a form of treatment in which a patient 
breathes 1 000/o oxygen at higher than normal atmospheric pressure that is 
greater than 1 atmosphere absolute (ATA) (Tarun Sahni, S. Hukku, Madhur 
Jain, Arun Prasad, Rajendra Prasad, Kuldeep Singh, 2004). Therapy is 
administered in special therapeutic pressurized chambers, which were earlier 
used primarily to treat illnesses of deep sea divers. In the sixties HBO went 
out of practice because of its use without adequate scientific validation. Over 
the last two decades, animal studies, clinical trials and well-validated clinical 
experience has proved efficiency of HBO in many indications and there is 
recently a renewed interest in this field all over the world. HBOT has 
become the definitive therapy for patients with decompression illness, gas 
embolism, and severe, acute carbon monoxide poisoning and is a widely 
accepted treatment for osteoradionecrosis, soft tissue radionecrosis 
(McDonagh M, september 2003), acute traumatic wounds, Crush injuries, 
Burns, Gas gangrene and compartment syndrome are indications where 
addition of Hyperbaric oxygen may be life and limb saving. Patients who 
have been suffering with non healing ulcers, Decubitus IDcers (Bed sores) 
and all late sequelae of Radiation therapy are also benefited with HBO 
therapy. Acute hearing loss and many neurological illnesses are also now 
known to possibly benefit from Hyperbaric Oxygen Therapy. With 
continuing growth all over the world Hyperbaric Medicine has found a 
distinct role in the modem era of evidence-based medicine (Tarun Sahni, S. 
Hukku, Madhur Jain, Arun Prasad, Rajendra Prasad, Kuldeep Singh, 2004). 
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WHO defines stroke as a rapid development of clinical signs of cerebral 
dysfunction with signs lasting ~ 24 hrs or leading to death with no apparent 
cause other than that of vascular origin. Stroke is also referred to as a sudden 
interruption of the blood supply to the brain, usually caused by a blocked 
artery or a ruptured blood vessel, leading to an interruption ofhomeostasis of 
cells, and symptoms such as loss of speech and loss of motor function 
(McDonagh M, september 2003). This condition represents a broad 
spectrum, from barely perceptible or mild disabilities to devastating ones 
which are characterized by acute and chronic phases and by changes over 
time in the type and degree of disability (McDonagh M, september 2003). 
The use of various diagnostic and therapeutic interventions including pre-
hospital intubation, intracranial pressure monitoring, intracranial pressure-
directed therapy, and head computed tomography scan utilization vary 
considerably among different centers. Such variation often signifies a lack of 
consensus on clinical effectiveness (Abbott, 1972). 
The purpose of this report is to give an analysis of the effectiveness of 
HBOT in patients after stroke. This can be achieved by illustrate the main 
pathophysiologic reactions, including inflammatory a reparatory 
mechanisms that all brain cells undergo during ischemie brain attack. The 
fundamentals of stroke where reviewed with the aim of achieving a clear 
view on the subject. Hence the recognition of therapeutic specificity that 
hyperbaric oxygen therapy (HBOT) offers. We also took a closer look on 
the basics of HBO, its history, physiological aspects, indications, the 
principles that accompany it. An analysis of methods, results, and 
conclusions of a literature review on the use of this therapy (HBOT) to treat 
manifestations of stroke in humans is assessed. 
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GENERAL PART 
========~==--·=-===================================== 
FUNDAMENTALS OF ACUTE ISCHEMIC STROKE 
BASIC PATHOPHYSIOLOGY 
Since the late 1980s, basic science research in the field of stroke has 
elucidated multiple pathways of cellular injury and repair after cerebral 
ischemia, resulting in the identification of several promising targets for 
neuroprotection. A large number of neuroprotective agents have been shown 
to reduce stoke-related damage in animal models. To date, however, no 
single agent has achieved success in clinical trials. Nevertheless, analysis of 
the reasons behind the failure of recent drug trials, combined with the 
success of clotlysing drugs in improving clinical outcome, has revealed new 
potential therapeutic opportunities and raised expectations that successful 
stroke treatment will be achieved in the near future (Aneesh B. Singhal, Eng 
H. Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). 
MECHANISMS OF ISCHEMIC CELL DEATH 
Ischemie stroke compromises blood flow and energy supply to the brain, 
which triggers at least five fundamental mechanisms that lead to cell death: 
excitotoxicity and ionic imbalance, oxidativelnitrative stress, inflammation, 
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apoptosis, and peri-infarct depolarization (Fig. 1) (Aneesh B. Singhal, Eng 
H. Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). 
These pathophysiological processes evolve in a series of complex spatial and 
temporal events spread out over hours or even days (Fig.2), have 
overlapping and redundant features, and mediate injury within neurons, glial 
cells, and vascular elements (Barone FC, Feuerstein GZ, 1999). 
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FIGURE 1 Major Pathways Implicated In Ischemie Cell Death 
Excitotoxicity, ionic imbalance, oxidative and nitrative stresses, and apoptotic-like 
mecbanisms. There is extensive interaction and overlap between multiple mediators of cell 
injury and cell death. After ischemie onset, loss of energy substrates leads to mitocbondrial 
dysfunction and the generation of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS). Additionally, energy deficits lead to ionic imbalance and excitotoxic 
glutamate effiux and build up of intracellular calcium. Downstream pathways ultimately 
inc:lude direct ftee radic:al damage to membrane lipids, cellular proteins, and DNA, as well 
as c:alcium-activated proteases, plus caspase cascades that dismantle a wide range of 
homeostatic, reparative, and cytoskeletal proteins. (Lo EH, Dalkara T, Moskowitz MA, 
2003) 
Figure 2 graphically shows the relative contribution of each process to the 
net stroke-related in jury. Within areas of severely reduced blood flow - the 
"core" of the ischemie territory - excitotoxic and necrotic cell death occurs 
within minutes, and tissue undergoes irreversible damage in the absence of 
prompt and adequate reperfusion. However, cells in the peripheral zones are 
supported by collateral circulation, and their fate is determined by several 
factors including the degree of ischemia and timing of reperfusion. In this 
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peripheral region, termed the "ischemie penumbra," cell death occurs 
relatively slowly via the active cell death mechanisms noted above; targeting 
these mechanisms provides promising therapeutic opportunities. (Aneesh B. 
Singhal, Eng H. Lo,Turgay Dalkara, Michael A.Moskowitz, 2006) 
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FIGURE 2 Putative Cascade of Damaging Events in the Focal Cere bral lschemia 
V ery early after the onset of the focal perfusion deficit. excitotoxic mechanisms can damage 
neurons and glia lethally. In addition, excitotoxicity triggers a number of events that can 
further contribute to the demise of the tissue. Such events include peri-infarct 
depolarizations and the more-delayed mechanisms of inflammation and programmed cell 
death. The x-axis reflects the evolution of the cascade over time, while the y-axis aims to 
illustrate the impact of each element ofthe cascade on the final outcome. (From Dimagel et 
al., Trends Neurosci 1999; 22: 391-397) 
EXCITOTOXICITY AND IONIC IMBALANCE 
Ischemie stroke results in impaired cellular energy metabolism and failure of 
energy-dependent processes such as the sodium-potassium A TPase. Loss of 
energy stores results in ionic imbalance, neurotransmitter release, and 
inhibition of the reuptake of excitatory neurotransmitters such as glutamate. 
Glutamate binding to ionotropic Nmethyl-D-aspartate (NMDA) and a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 
promotes excessive calcium influx that triggers a wide array of downstream 
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phospholipases and proteases, which in turn degrade membranes and 
proteins essential for cellular integrity (Aneesh B. Singhal, Eng H. 
Lo, Turgay Dalkara, Michael A.Moskowitz, 2006). Experimental models of 
stroke, indicates extracellular glutamate levels increase in the 
microdialysate, and glutamate receptor blockade attenuates stroke lesion 
volumes (Shimizu-Sasamata M, Bosque-Hamilton P, Huang PL, Moskowitz 
MA,Lo EH, 1998) (Wang X, Shimizu-Sasamata M, Moskowitz MA, 
Newcomb ~ Lo EH, 2001). NMDA receptor antagonists prevent the 
expansion of stroke lesions in part by blocking spontaneous and spreading 
depolarization of neurons and glia (cortical spreading depression) 
(Hossmann.KA, 1996). Recent studies noted that activation of the 
metabotropic subfamily of receptors has been implicated in glutamate 
excitotoxicity (Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, 
De Blasi A, Melchiorri D, Flor PJ, Nicoletti F , 2001). Up - and down 
regulation of specific glutamate receptor subunits contribute to stroke 
pathophysiology in different ways (Michaelis.EK, 1998). For instance, after 
global cerebral ischemia, there is a relative reduction of calcium 
impenneable GluR2 subunits in AMPA-type receptors, making these 
receptors more permeable to deleterious calcium influx (Pellegrini-
Giampietro DE, Zukin RS, Bennett MV, Cho S, Pulsinelli WA , 1992). 
Antisense knock down of calcium-impermeable GluR2 subunits significantly 
increased hippocampal injury in a rat model of transient global cerebral 
ischemia, confinning the importance of these regulatory subunits in 
mediating neuronal vulnerability (Oguro K, Oguro N, Kojima T, Grooms 
SY, Calderone A,Zheng X, Bennett MV, Zukin RS, 1999). Depending upon 
the subtype, metabotropic glutamate receptors can trigger either pro-survival 
or pro-death signals in ischemie neurons (Bruno V, Battaglia G, Copani A, 
D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F , 
2001). Understanding how the expression of specific glutamate receptor 
subunits modifies cell survival should stimulate the search for stroke 
neuroprotective drugs that selectively target specific subunits. lonotropic 
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glutamate receptors also promote perturbations in ionic homeostasis that 
play a critical role in cerebral ischemia (Aneesh B. Singhal, Eng H. 
Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). For example, L-, P/Q-, 
and N-type calcium channel receptors mediate excessive calcium influx, and 
calcium channel antagonists reduce ischemie brain injury in preclinical 
studies (Hom J, Limburg M, 2001) (Zipfel GJ, Lee JM, Choi DW, 1999). 
Zinc is stored in vesicles of excitatory neurons and co-released upon 
depolarization after focal cerebral ischemia, resulting in neuronal death 
(Weiss JH, Hartley DM, Koh JY, Choi DW, 1993) (Sorensen JC, Mattsson 
B, Andreasen A, Johansson BB, 1998). Recently, imbalances in potassium 
have also been implicated in ischemie cell death (Aneesh B. Singhal, Eng H. 
Lo, Turgay Dalkara, Michael A.Moskowitz, 2006). Compounds that 
selectively modulate a class of calcium sensitive high conductance 
potassium (maxi-K) channels protect the brain against stroke in animal 
models (Gribkoff VK, Starrett JE Jr., Dworetzky SI, Hewawasam P, 
Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, 
Johnson G, Krishnan BS, Kinney GG, Lombardo LA,Meanwell 
NA,Molinoff PB,Myers RA,Moon SL, Ortiz A, Pajor L, Pieschl RL, Post-
Munson DJ" 200 I). 
OXIDATIVE AND NITRATIVE STRESS 
Reactive oxygen species (ROS) such as superoxide and hydroxyl radicals are 
known to mediate reperfusion-related tissue damage in several organ 
systems including the brain, heart, and kidneys (Chan, 2001). Oxygen free 
radicals are normally produced by the mitochondria during electron 
transport, and, after ischemia, high levels of intracellular Ca2+, Na+, and 
ADP stimulate excessive mitochondrial oxygen radical production. Oxygen 
191 Page 
radical production may be especially harmful to the injured brain because 
levels of endogenous antioxidant enzymes [including superoxide dismutase 
(SOD), catalase, glutathione], and antioxidant vitamins (e.g., alpha-
tocopherol, and ascorbic acid) are nonnally not high enough to match excess 
radical fonnation. After ischemia reperfusion, enhanced production of ROS 
overwhelms endogenous scavenging mechanisms and directly damages 
lipids, proteins, nucleic acids, and carbohydrates (Aneesh B. Singhal, Eng H. 
Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). lmportantly, oxygen 
radicals and oxidative stress facilitate mitochondrial transition pore (MTP) 
formation, which dissipates the proton motive force required for oxidative 
phosphorylation and ATP generation (Kroemer G, Reed JC, 2000). As a 
result, mitochondria release apoptosis-related proteins and other constituents 
within the inner and outer mitochondrial membranes (Bemardi P, Petronilli 
V, Di Lisa F, Forte M, 2001). Upon reperfusion and renewed tissue 
oxygenation, dysfunctional mitochondria may generate oxidative stress and 
MTP fonnation. Oxygen radicals are also produced during enzymatic 
conversions such as the cyclooxygenase-dependent conversion of 
arachidonic acid to prostanoids and degradation of hypoxanthine, especially 
upon reperfusion. Furthennore, free radicals are also generated during the 
inflammatory response after ischemia (see below). Not surprisingly then, 
oxidative sttess, excitotoxicity, energy failure, and ionic imbalances are 
inextricably linked and contribute to ischemie cell death. Oxidative and 
nitrative sttesses are modulated by enzyme systems such as SOD and the 
nitric oxide synthase (NOS) family (Aneesh B. Singhal, Eng H. Lo,Turgay 
Dalkara, Michael A.Moskowitz, 2006). The important role of SOD in 
cerebral ischemia is demonstrated in studies showing that mice with 
enhanced SOD expression show reduced injury after cerebral ischemia 
whereas those with a deficiency show increased injury (Kinouchi H, Epstein 
CJ,Mizui T, Carlson E, Chen SF, ChanPH, 1991), (Sheng H, Bart RD,Oury 
TD,Pearlstein RD,Crapo JD,Warner DS, 1999) (Kim GW, Kondo T, Noshita 
N, Chan PH, 2002). Similarly, in the case ofNOS, stroke-induced injury is 
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attenuated in mice with deficient expression of the neuronal and inducible 
NOS isoforms (Huang Z, Huang PL, Panahian N, Dalkara T, Fishman 
MCMoskowitz MA , 1994), (Iadecola C, Zhang F, Casey R,Nagayama 
M,Ross ME, 1997). NOS activation during ischemia increases the generation 
of NO production, which combines with superoxide to produce 
peroxynitrite, a potent oxidant (Beckman JS, Beckman TW, Chen J, 
Marshall PA, Freeman BA, 1999). The generation of NO and oxidative 
stress is also linked to DNA damage and activation of poly(ADP-ribose) 
polymerase-1 (P ARP-1 ), a nuclear enzyme that facilitates DNA repair and 
regulates transcription (Zhang J, Dawson VL, Dawson TM, Snyder SH, 
1994). PARP-1 catalyzes the transformation of b-nicotinamide adenine 
dinucleotide (NAD+) into nicotinamide and po ly (ADP-ribose ). In response 
to DNA strand breaks, P ARP-1 activity becomes excessive and depletes the 
cell of NAD+ and possibly ATP (Aneesh B. Singhal, Eng H. Lo, Turgay 
Dalkara, Michael A.Moskowitz, 2006). Inhibiting PARP-1 activity or 
deleting the parp-1 gene reduces apoptotic and necrotic cell death (Eliasson 
MJ, Sampei K,Mandir AS,Hurn PD,Traystman RJ Bao J, Pieper A,Wang 
ZQ, Dawson TM, Snyder SH, Dawson VL, 1997), (Endres M, Wang ZQ, 
Namura S,Waeber C,Moskowitz MA, 1997), pointing to the possible 
relevance ofthis enzyme as a target for stroke therapy. 
APOPTOSIS 
Apoptosis, or programmed cell death (Yuan J, Yankner BA , 2000), is 
characterized histologically by cells positive for terminaldeoxynucleotidyl-
transferase-mediated dUTP nick end labeling (TUNEL) that exhibit DNA 
laddering. Necrotic cells, in contrast, show mitochondrial and nuclear 
swelling, dissolution of organelles, nuclear chromatin condensation, 
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followed by rupture of nuclear and cytoplasmic membranes, and the 
degradation of DNA by random enzymatic cuts. Cell type, cell age, and 
brain location render cells more or less resistant to apoptosis or necrosis. 
Mild ischemie injury preferentially induces cell death via an apoptotic-like 
process rather than necrosis, although "aponecrosis" more accurately 
describes the pathology. Apoptosis occurs via caspase-dependent as well as 
caspase-independent mechanisms (Fig. 3). Caspases are protein-cleaving 
enzymes (zymogens) that belong to a family of cysteine aspartases 
constitutively expressed in both adult and especially newbom brain cells, 
particularly neurons (Aneesh B. Singhal, Eng H. Lo,Turgay Dalkara, 
Michael A.Moskowitz, 2006). 
The mechanisms of cleavage and activation of caspases in human brain are 
believed to be similar to those documented in experimental models of stroke, 
trauma, and neurodegeneration (Chopp M, Chan PH, Hsu CY, Cheung ME, 
Jacobs TP, 1996). Apoptogenic triggers include oxygen free radicals, Bcl2, 
death receptor ligation, DNA d.amage, and possibly lysosomal protease 
activation (Nicotera P, Lipton SA, 1999), (Budd SL, Tenneti L, Lishnak T, 
Lipton SA, 2000), (Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt 
R Vogel J, Schenkel J, Herdegen T, Debatin KM, 1999),(GS, 2001). 
Since caspase-dependent cell death requires energy in the form of ATP, 
apoptosis predominantly occurs in the ischemie penumbra (which sustains 
milder injury) rather than in the ischemie core, where ATP levels are rapidly 
depleted (Nicotera P, Leist M, Fava E, Berliocchi L,Volbracht C, 2000). 
Microglial cells become activated in these areas, this may be either as a sign 
of neuronal deafferentation or of neuronophagia (Pappata, S., Levasseur, 
M.m Gunn, R.N.,Myers, R., Crouzel, C.,Syrota, A.,Jones, T., Kreutzberg, 
G.W., and Banati, R.B. , 2000). Glial cells may be involved in stroke-
induced apoptosis in several ways: 
•!• By producing signals that induce apoptosis in neurons 
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•) By dying apoptotically triggered by the same signals and in a manner 
similar to that of neurons (in particular oligodendrocytes: Mabuchi 
et al., 2000) 
<• By self-elimination via apoptosis 
+ By producing factors that protect neurons against apoptosis 
All these processes are closely connected with inflammation. Inflammation 
produces toxins like oxygen free radicals that induce mitochondrial and 
DNA damage as important upstream mediators of apoptosis in neurons and 
oligodendrocytes. In addition, apoptosis is a critical mechanism in limiting 
and terminating inflammation, although it is controversial whether 
inflammatory cells themselves are eliminated by apoptosis Dimagle et al. It 
is very likely that astrocytes play a major role in limiting the growth of 
ischemie lesions, and that antiapoptotic mechanisms are a key element to 
astrocyte-mediated neuroprotection after stroke. Astrocytes are a major 
source of growth factors that protect neurons against ischemie damage. 
Reactive astrocytes are a major source of growth factors that protect neurons 
against ischemie damage. Reactive astrocytes produce nerve growth factor, 
basic fibroblast growth factor, brain-derived nerve growth factor, ciliary 
neurotrophic factor, insulin-like growth factor-1 among others. 
(W.J.Koroshetz, R.G.González, 2006) 
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FIGURE 3 Cell Death Pathways Relevant To An Apoptic-Like Mechanism In 
Cerebral lschemia: 
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Release of cytochrome c (Cyt.c) :from the mitochondria is modulated by pro- as well as anti-
apoptotic Bcl2 family members. Cytochrome c release activates downstream caspases 
through apoptosome formation (not shown) and caspase activation can be modulated by 
secondary mitochondria-derived activator of caspase (Smac/Diablo) indirectly through 
suppressing protein inhibitors of apoptosis (lAP). Effector caspases ( caspases 3 and 7) target 
several substrates, which dismantle the cell by cleaving homeostatic, cytoskeletal, repair, 
metabolic, and cell signaling proteins.Caspases also activate caspase-activated 
deoxyribonuclease (CAD) by cleavage of an inhibitor protein (/CAD). Caspase-independent 
cell death may also be important. One mechanism proposes that poly-ADP (n"bose) 
polymerase activation (P ARP) promotes the release of apoptosis-inducing factor (AlF), 
which translocates to the nucleus, binds to DNA, and promotes cell death through a 
mechanism that awaits clarification. (From Lo et al., Nat Rev Neurosci 2003, 4: 399-415) 
INFLAMMATION 
Inflammation is intricately related to the onset of stroke, and to subsequent 
stroke-related tissue damage. lnflammation within the arterial wall plays a 
vital role in promoting atherosclerosis (Elkind MS, Cheng J, Boden-Albala 
B, Rundek T, Thomas J,Chen H, Rabbani LE, Sacco RL, 2002). Arterial 
thrombosis (usually associated with ulcerated plaques) is triggered by 
multiple processes involving endothelia! activation, as well as pro-
inflammatory and pro-thrombotic interactions between the vessel wall and 
circulating blood elements (Aneesh B. Singhal, Eng H. Lo, Turgay Dalkara, 
Michael A.Moskowitz, 2006). 
Ischemie stroke-related brain injury itself triggers inflammatory cascades 
within the parenchyma that further amplify tissue damage (Barone FC), (de I 
Zoppo G, Ginis I, Hallenbeck JM, ladecola C,Wang X,Feuerstein GZ , 
2000). As reactive microglia, macrophages, and leukocytes are recruited into 
ischemie brain, inflammatory mediators are generated by these cells as well 
as by neurons and astrocytes (Aneesh B. Singhal, Eng H. Lo, Turgay 
Dalkara, Michael A.Moskowitz, 2006). Inducible nitric oxide synthase 
(iNOS), cyclooxygenase-2 (COX-2), interleukin-1 (IL-1), and monocyte 
chemoat tractant protein-1 (MCP-1) are key inflammatory mediators, as 
evidenced by attenuated ischemie injury in mutant mice with targeted 
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disruption of their genes (Hughes PM, Allegrini PR, Rudin M, Perry VH, 
Mir AK, Wiessner C , 2002), (Boutin H,LeFeuvre RA,Horai R,Asano M, 
Iwakura Y ,Rothwell NJ, 2001). Initially after occlusion, there is a transient 
up regulation of immediate early genes encoding transcription factors (e.g., 
c-fos, c-jun) that occurs within minutes. This is followed by a second wave 
of heat shock genes (e.g., HSP70, HSP72) that increase within 1-2 h and 
then decrease by 1-2 days. Approximately 12-24 h after a stroke, a third 
wave comprised of chemokines and cytokines is expressed ( e.g., IL-1, IL-6, 
IL-8, TNF-a, MCP-1, etc.). It is not known whether these three waves are 
causally related. Inflammatory cascades stimulate both detrimental and 
potentially beneficial pathways after ischemia (Aneesh B. Singhal, Eng H. 
Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). Similarly, the peptide 
vascular endothelial growth factor (VEGF) exacerbates edema in the acute 
phase of cerebral ischemia but promotes vascular remodeling during stroke 
recovery (Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, 
Bruggen N, Chopp M, 2000). Ultimately, the net effect of these mediators 
depends upon the stage of tissue injury or the predominance of a single 
signaling cascade among multiple divergent pathways (Aneesh B. Singhal, 
Eng H. Lo, Turgay Dalkara, Michael A.Moskowitz, 2006). 
PERI-INFARCT DEPOLARIZA TIONS 
Brain tissue depolarizations after ischemie stroke are believed to play a vital 
role in recruiting adjacent penumbral regions of reversible injury into the 
core area of infarction. Cortical spreading depression (CSD) is a self-
propagating wave of electrochemical activity that advances through neural 
tissues at a rate of 2-5 mm/min, causing prolonged (1-5 min) cellular 
depolarization, depressed neuro-electrical activity, potassium and glutamate 
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release into adjacent tissue and reversible loss of membrane ionic gradients 
(Aneesh B. Singhal, Eng H. Lo, Turgay Dalkara, Michael A.Moskowitz, 
2006). CSD is associated with a change in the levels of numerous factors 
including immediate early genes, growth factors, and inflammatory 
mediators such as interleukin- lb and TNF-a (Jander S, Schroeter M, Peters 
O, Witte OW, Stoll G , 2001 ). CSD is a reversible phenomenon, and, while 
implicated in conditions such as migraine, reportedly does not cause 
pennanent tissue in jury in humans (Aneesh B. Singhal, Eng H. Lo, Turgay 
Dalkara, Michael A.Moskowitz, 2006). In severely ischemie regions, energy 
failure is so profound that ionic disturbances and simultaneous 
depolarizations become pennanent, a process tenned anoxic depolarization 
(Hansen AJ,Nedergaard M, 1988). In penumbral regions after stroke, where 
blood supply is compromised, spreading depression exacerbates tissue 
damage, perhaps due to the increased energy requirements for reestablishing 
ionic equilibrium in the metabolically compromised ischemie tissues 
(Aneesh B. Singhal, Eng H. Lo, Turgay Dalkara, Michael A.Moskowitz, 
2006). In this context, spreading depression waves are referred to as peri-
infarct depolarizations (PIDs ), reflecting their pathogenic role and similarity 
to anoxic depolarization (Hossmann.KA, 1996). PIDs have been 
demonstrated in mice rat, and cat stroke models (Strong AJ, Smith 
SE,Whittington DJ,Meldrum BS, Parsons AA,Krupinski J,Hunter AJ,Patel 
S,Robertson C, 2000), (Gill ~ Andine P, Hillered L, Persson L, Hagberg H, 
1992); however, their relevance to human stroke pathophysiology remains 
unclear (Aneesh B. Singhal, Eng H. Lo, Turgay Dalkara, Michael 
A.Moskowitz, 2006). In the initial 2-6 h after experimental stroke, PIDs 
result in a step-wise increase in the region of core-infarcted tissue into 
adjacent penumbral regions and the incidence and total duration of spreading 
depression is shown to correlate with infarct size (lijima T, Mies G, 
Hossmann KA , 1992), (Busch E, Gyngell ML, Eis M, Hoehn-Berlage M, 
Hossmann KA, 1996), (Dijkhuizen RM, Beekwilder JP, van der Worp HB, 
Berkelbach van der Sprenkel JW, Tulleken KA, Nicolay K, (1999). Recent 
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evidence suggests that PIDs contribute to the expansion of the infarct core 
throughout the period of infarct maturation (Hartings JA, Rolli ML, Lu XC, 
Tortella FC , 2003). Inhibition of spreading depression using 
pharmaceutical agents such as NMDA or glycine antagonists or 
physiological approaches such as hypothennia, may be an important strategy 
to suppress the expansion of an ischemie lesion (Hartings JA, Rolli ML, Lu 
XC, Tortella FC, 2003), (Tatlisumak T, Takano K, Meiler MR, Fisher M, 
1998) (Chen Q, Chopp M, Bodzin G, Chen H, 1993). 
GREY MATTER VERSUS WHITE MATTER ISCHEMIA 
In addition to the size of the stroke, its location, and the relative involvement 
of gray versus white matter are key determinant& of outcome. For example, 
smalt white matter strokes often cause extensive neurologie deficits by 
interrupting the passage of large axonal bwdles such as those within the 
intemal capsule. Blood :tlow in white matter is lower than in gray matter, 
and white matter ischemia is typically severe, with rapid cell swelling and 
tissue edema because there is little collateral blood supply in deep white 
matter. Moreover, cells within the gray and white matter have different 
susceptibilities to ischemie in jury (Aneesh B. Singhal, Eng H. Lo, Turgay 
Dalkara, Michael A.Moskowitz, 2006). Amongst the neuronal population, 
well-defined subsets (the CAl hippocampal pyramidal neurons, cortical 
projection neurons in layer 3, neurons in dorsolateral striatum, and cerebellar 
Purkinje cells) are particularly susceptible and wdergo selective death after 
transient global cerebral ischemia (Petty MA, Wettstein JG , 1999). The 
major cell types composing the neurovascular module within white matter 
include the endothelial cell, perinodal astrocyte, axon, oligodendrocyte, and 
myelin. In general, oligodendrocytes are more vulnerable than astroglial or 
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endothelial cells (Aneesh B. Singha~ Eng H. Lo,Turgay Dalkara, Michael 
A.Moskowitz, 2006). There are important differences in the 
pathophysiology of white matter ischemia as compared to that of gray 
matter, which have implications for therapy (PK, 1998). In the case of 
excitotoxicity, since the white matter lacks synapses, neurotransmitter 
release from vesicles does not occur despite energy depletion and 
neurotransmitter accumulation (Aneesh B. Singhal, Eng H. Lo,Turgay 
Dalkara, Michael A.Moskowitz, 2006). Instead, there is reversal of Na+ -
dependent glutamate transport (Li S, Mealing GA, Morley P, S tys PK , 
1999), resulting in glutamate toxicity with subsequent AMP A receptor 
activation, and excessive accumulation of calcium, which in turn activates 
calcium-dependent enzymes such as calpain, phospholipases, and protein 
kinase C, resulting in irreversible injury (Aneesh B. Singhal, Eng H. 
Lo, Turgay Dalkara, Michael A.Moskowitz, 2006). The distinct lack of 
AMP A receptors expressing calcium impenneable GluR2 subunits may 
make oligodendroglia particularly vulnerable to excitotoxic injury 
(McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP, 1998). 
In the case of oxidative stress-induced white matter injury, the severity of 
injury appears to be greater in large axons as compared to small axons 
although the mechanisms underlying these differences need further study 
(Petty MA, Wettstein JG, 1999). Despite these differences between gray and 
white matter in jury, several common cascades of injury do exist (Aneesh B. 
Singhal, Eng H. Lo, Turgay Dalkara, Michael A.Mosk.owitz, 2006). 
Damaged oligodendrocytes express death signals such as TNF and Fas 
ligand, and recruit caspase-mediated apoptotic-like pathways (Gu C, 
Casaccia-Bonnefil P, Srinivasan A, Chao MV , 1999). Degradation of 
myelin basic protein by matrix metalloproteinases (MMPs ), and upregulation 
of MMPs in autopsied samples from patients with vascular dementia suggest 
that proteolytic pathways are also recruited in white matter. These pathways 
might serve as common targets for stroke therapy (Chandler S, Coates R, 
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Gearing A, Lury J,Wells G, Bone E, 1995) (Rosenberg GA, Sullivan N, Esiri 
MM,2001). 
THE NEUROVASCULAR UNIT 
Neurovascular unit is a modular concept that emphasises the dynamics of 
vascular, cellular, and matrix signaling in the maintainance ofthe integrity of 
brain tissue within both the gray and white matter, and its importance to the 
pathophysiology of conditions such as stroke, vascular dementia, migraine, 
trauma, multiple sclerosis, and possibly the aging brain (Fig. 4) (Aneesh B. 
Singhal, Eng H. Lo, Turgay Dalkara, Michael A.Moskowitz, 2006). The 
neurovascular unit places stroke in the context of an integrative tissue 
response in which all cellular and matrix elements, not just neurons or blood 
vessels, are players in the evolution oftissue injury (Aneesh B. Singhal, Eng 
H. Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). For instance, efficacy 
of the blood-brain barrier is critically dependent upon endothelial-
astrocyte-- matrix interactions (Petty MA, Lo EH , 2002). 
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FIGURE 4 Schematic View Of The Neurovascular Unit Or Module And Some Of 
lts Components: 
Circulating blood elements, endothelial cells, astrocytes, extracellular matrix, basal lamina, 
adjacent neurons, and pericytes. After ischemia, perturbations in neurovascular functional 
integrity initiate multiple cascades of injury. Upstream signals such as oxidative stress 
together with neutrophil and/or platelet interactions with activated endothelium upregulate 
matrix metalloproteinases (MMPs), plasminogen activators and other proteases which 
degrade matrix and lead to blood-brain barrier leakage. Intlammatory infiltrates through the 
damaged blood-brain barrier amplify brain tissue injury. Additionally, disruption of cell 
matrix homeostasis may also trigger anoikis-like cell death in both vascular and 
parenchymal comparbnents. Overlaps with excitotoxicity have also been documented via t-
PA-mediated interactions with the NMDA receptor that augment ionic imbalance and cell 
death. (t-PA Tissue plasm.inogen activator) {Aneesh B. Singhal, Eng H. Lo,Turgay Dalkara, 
Michael A.Moskowitz, 2006). 
Disruption of the neurovascular matrix, which includes basement membrane 
components such as type N collagen, heparan sulfate proteoglycan, laminin, 
and fibronectin, upsets the cell-matrix and cell-cell signaling that maintains 
neurovascular homeostasis. Although many proteases including cathepsins 
and heparanases contribute to extracellular matrix proteolysis, in the context 
of stroke, plasminogen activator (PA) and MMP are probably the two most 
important. This is because tissue plasminogen activator (t-PA) has been used 
successfully as a stroke therapy, and because emerging data show important 
linkages between t-PA, MMPs, edema, and hemorrhage after stroke (Aneesh 
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B. Singhal, Eng H. Lo, Turgay Dalkara, Michael A.Moskowitz, 2006). The 
MMPs are zinc endopeptidases produced by all cell types of the 
neurovascular unit (Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards 
DR, 1998), that are secreted as zymogens requiring cleavage for enzymatic 
activation. MMPs can be classified into: 
)I- gelatinases (MMP-2 and -9), 
)I- collagenases (MMP-1, -8, -13), 
)I- stromelysins (MMP-3, -10, -ll), 
> membrane-type MMPs {MMP-14, -15, -16, -17), and others (e.g., 
MMP-7 and -12) (Cumer ML, Opdenakker G, 1999). 
Together with the PA system, MMPs play a central role in brain 
development and plasticity as they modulate extracellular matrix to allow 
neurite out growth and cell migration (Yong VW, Power C, Forsyth P, 
Edwards DR, 2001). Upstream triggers of MMP include MAP kinase 
pathways and oxidative stress (Wang X,Mori T, Jung JC, Fini ME, Lo EH, 
2002), (Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH, 2001). 
MMP signaling is intricately linked to other well-recognized pathways after 
stroke, including oxidative and nitrative stress, caspase-mediated cell death 
excitotoxicity, and neuro-inflammation (Gu Z, K.aul M,Yan B, Kridel SJ, 
Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA, 2002), (Justicia 
C,Panes J,Sole S,Cervera A,Deulofeu R,Chamorro A, Planas AM , 2003) 
(Lee SR, Lo EH , 2004). 
Several experimental as well as human studies provide evidence for a major 
role of MMPs (particularly MMP-9) in ischemie stroke, primary brain 
hemorrhage, blood-brain barrier disru.ption and post-ischemie or reperfusion 
hemorrhage (Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC,Kawase 
M, Massengale J, Chan PH, 1999),(Asahi M,Asahi K, Jung JC, del Zoppo 
GJ, Fini ME, Lo EH, 2000) (Montaner J,Alvarez-Sabin J,Molina C,Angles 
A,AbilleiraS, Arenillas J, Gonzalez MA, Monasterio J, 2001), (Sumii T,Lo 
EH, 2002), (Abilleira S,Montaner J,Molina CA,Monasterio J, Castillo 
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J,Alvarez-Sabin J, 2003), (Fukuda S, Fini CA,Mabuchi T,Koziol JA, 
Eggleston LL Jr., del Zoppo GJ, 2004). Emerging data suggest that 
administered t-PA upregulates MMP-9 via the low-density lipoprotein 
receptor-related protein (LRP), which avidly binds t-PA and possesses 
signaling properties (Wang :X,Lee SR,Arai K, Tsuji K,Rebeck GW,Lo EH, 
2003). Targeting the t-PA-LRP-MMP pathway may offer new therapeutic 
approaches for improving the safety pro:file of t-PA in patients with stroke 
(Aneesh B. Singhal, Eng H. Lo, Turgay Dalkara, Michael A.Moskowitz, 
2006). 
NEUROPROTECTION 
Neuroprotection can be de:fined as the protection of cell bodies and neuronal 
and glial processes by strategies that impede the development of irreversible 
ischemie injury by effects on the cellular processes involved. 
Neuroprotection can be achieved using pharmaceutical or physiological 
therapies that directly inhibit the biochemical, metabolic, and cellular 
consequences of ischemie injury, orby using indirect approaches such as t-
PA and mechanical devices to restore tissue perfusion (Aneesh B. Singhal, 
Eng H. Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). The overlapping 
complex pathways involving excitotoxicity, ionic imbalance, oxidative and 
nitrative stress, and apoptotic like mechanisms have been reviewed above. 
Each of these pathways offers several potential therapeutic targets, several of 
which have proveď successful in reducing ischemie injury in animal models. 
However, the successful translation of experimental results into clinical 
practice remains elusive (Aneesh B. Singhal, Eng H. Lo,Turgay Dalkara, 
Michael A.Moskowitz, 2006). 
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CORE AND PENUMBRA 
The core generally defined as that part of the ischemie region that is 
irreversibly injured, while the penumbra is the area of brain that is 
underperfused and is in danger of infracting. These are useful coneepts for 
several reasons. If they can be identified in the acute ischemie stroke patient 
they provide prognostie information, and may help guide the patienť s 
management. Importantly, it is now elear that neuroimaging can provide 
excellent estimates of the core and the penumbra in individual patients 
(W.J.Koroshetz, R.G.González, 2006). 
FIGURE S ACA Colleteral Flow, FIGURE 6 ACA Collateral Flow after MCA 
Occlusion 
(W.J.Koroshetz, R.G.González, 2006) 
To illustrate the corelpenumbra eoncept, let us consider the hypothetical ease 
of an embolus to the main stem portion (Ml) of the middle cerebral artery 
(MCA). The MCA along with the anterior eerebral artery (ACA) arise from 
the internal carotid artery (ICA) at the base ofthe frontallobe (Fig. 5). When 
an embolus lodges in the Ml segment ofthe MCA, the MCA territory ofthe 
brain becomes underperfused (Fig.6). However, in many cases the collateral 
eirculation from the ACA and posterior cerebral artery ean compensate to 
some degree. The amount of collateral flow detennines the size of the core 
and the penumbra (Figs. 7, 8). 
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FIGURE 7 Penumbra and Core after MCA Occlusion 
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FIGURE 8 Core and Penumbra, FIGURE 9 Blood Flow, Time, Core and Penumbra 
(W.J.Koroshetz, R.G.González, 2006) 
However, it is critical to understand that both the core and penumbra are 
dynamic entities that depend on the complex physiology that is playing out 
in the acutely ischemie brain. If the occlusion is not removed, the core size 
usually increases, while the salvageable penumbra decreases with time (Fig. 
9). The rate of change in the size of the core and the penumbra depends on 
the blood flow provided by the collaterals (W.J.Koroshetz, R.G.González, 
2006). 
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IDENTIFYING THE ISCHEMIC PENUMBRA 
While irreversible cell death begins within minutes after stroke onset within 
regions of maximally reduced blood flow (the infarct "core"), for several 
hours there exists a surrounding "penumbra" of ischemie but noninfarcted 
tissue that is potentially salvageable (Hossmann, 1994), (Baron, 2001), 
(Ginsberg MD, Pulsinelli WA, 1994), (Markus R, Reutens DC, Kazui S, 
Read S,Wright P, Pearce DC,Tochon-Danguy HJ, Sachinidis R,Donnan GA, 
2004). The concept of an "ischemie penumbra" provides a rationale for the 
use of neuroprotective drugs and reperfusion techniques to improve outcome 
after acute ischemie stroke. Then again, the extent of penumbral tissue is 
thought to diminish rapidly with time, hence the therapeutic time window is 
narrow (Aneesh B. Singhal, Eng H. Lo,Turgay Dalkara, Michael A. 
Moskowitz, 2006). 
INDUCED HYPERTENSION 
The ischemie penumbra shows impaired autoregulation, and appears to be 
particularly sensitive to blood pressure manipulation. The rationale for using 
induced hypertension as a stroke therapy is provided by early studies 
showing that raising mean arterial pressure results in improved cerebral 
perfusion within the penumbra, and a concomitant retum of electrical 
activity (Aneesh B. Singhal, Eng H. Lo,Turgay Dalkara, Michael 
A.Moskowitz, 2006). In animal models of focal cerebral ischemia, induced 
hypertension therapy was found to augment cerebral blood flow, attenuate 
brain injury, and improve neurological function (Hayashi S, Nehls DG, 
Kieck CF, Vielma J, DeGirolami U, Crowell RM, 1984), (Cole 
DJ,Matsumura JS, Drummond JC, Schell RM, 1992). 
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HYPEROXIA 
Tissue hypoxia plays a critical role in the primary and secondary events 
leading to cell death after ischemie stroke (Lo EH, Dalkara T, Moskowitz 
MA , 2003); therefore, increasing brain oxygenation has long been 
considered a logical stroke treatment strategy. Theoretically, oxygen should 
be an excellent drug for treating stroke since it has distinct advantages over 
pharmaceutical agents: it easily diffuses across the blood-brain barrier, has 
multiple beneficial biochemical, molecular, and hemodynamic effects, it is 
well tolerated, and can be delivered in high doses without dose-limiting side-
effects ( except in patients with chronic obstructive pulmonary disease) 
(Aneesh B. Singhal, Eng H. Lo, Turgay Dalkara, Michael A.Moskowitz, 
2006). Experimental studies have shown that supplemental oxygen favorably 
alters the levels of glutamate, lactate, bcl2, manganese superoxide dismutase, 
cyclooxygenase-2, and inhibits cell-death mechanisms such as apoptosis 
(Yin W, Badr AE, Mychaskiw G, Zhang JH , 2002), (Yin D, Zhou C,K.usaka 
I, Calvert JW, Patent AD,Nanda A, Zhang JH , 2003), (Wada K,Miyazawa 
T,Nomura N,Tsuzuki N,Nawashiro H, Shima K , 2001), (Menzel M, 
Doppenberg EM, Zauner A, Soukup J, Reinert MM,Bullock R , 1999), 
(Rockswold SB, Rockswold GL, Vargo JM, Erickson CA, Sutton RL, 
Bergman TA, Biros MH, 2001), (Zhang JH, Singhal AB, Toole JF, 2003), 
(Badr AE,Yin W,Mychaskiw G, Zhang JH, 2001). Because the rationale for 
oxygen in stroke is so compelling, numerous groups have focused on it as a 
potential therapy. Hyperbaric oxygen therapy (HBO) has been widely 
studied because it significantly raises brain tissue partial pressure of oxygen 
(brain pti02), a factor believed critical for effective neuroprotection (Aneesh 
B. Singhal, Eng H. Lo,Turgay Dalkara, Michael A.Moskowitz, 2006). 
Clinical improvement during exposure to HBO was observed nearly 40 years 
ago (Ingvar HD, Lassen NA, 1965). 
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CAUSES OF ISCHEMIC STROKE 
Ischemie stroke occurs due to a multitude of underlying pathologic 
processes. The bmin is such an exquisite reporting system that infarcts below 
the size that cause clinical signs in other organ systems can cause major 
disability if they affect bmin. About 85% of all strokes are due to ischemia, 
and in the majority of ischemie stroke the mechanism responsible is 
understood (Fig. ll). An illustration of the causes of the majority of 
ischemie strokes is shown in Fig. 1 O, including atherosclerotic, 
cerebrovascular, cardiogenic, and lacunar (penetrating vessel) mechanisms. 
However, in about 30% of cases, the underlying causes are not known and 
these are termed cryptogenic strokes (W J.Koroshetz, R.G.González, 2006). 
The pathways that lead to ischemie stroke are reviewed bellow. 
I 
l 
---------------- -----
--- ----·-·---·- ----
Stroke frequency by mechanism 
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FIGURE 10 Stroke Frequency by Mechanism (W.J.Koroshetz, R.G.González, 
2006) 
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FIGURE ll the most frequent sites of arterial and cardiac abnormalities causing 
ischemie stroke. (ALBERS GW, AMARENCO P. EASTON JD. SACCO RL. 
TEAL P. 2004) 
FIGURE12 Right Intemal Carotid Artery 
(W.J.KOROSHETZ. R.G.GONZÁLEZ. 2006) 
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FIGURE 13 Intemal Carotid 
Artery Feeds the Middle Cerebra 
Artery and Anterior Cerebral 
Artery 
In numerous respects stroke is a preventable disorder. Prevention is the 
target of a variety of programs to reduce risk factors for stroke. The greatest 
stroke risk occurs in those with previous transient ischemie attack or 
previous stroke. For these patients risk factor reduction is essential and risk 
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mav be associated with soecific cardiovascular. cerebrovascular or 
hematolosric disorders. Secondarv vascular risk has been shown to decrease 
with treatment of hvoertension and hvoerlioidemia and the institution of 
antiolatelet drue treatment. Globallv. hvoertension is the most simificant 
risk factor for stroke. both ischemie and hemorrhasric. Elevation in blood 
oressure olavs a large role in the develooment of vascular disease. including 
coronarv heart disease. ventricular failure. atherosclerosis of the aorta and 
cerebrovascular arteries. as well as small vessel occlusion. Diabetes mellitus 
ranks highlv as a stroke risk factor. Unless it is auelled. the current epidemie 
of obesitv is exoected to fuel greater strok.e risk in the near future. 
Hyperlioidemia. tobacco abuse, cocaine and narcotic abuse, and lack of 
physical exercise also contribute to population stroke risk. There is an 
increased incidence of stroke during seemingly nonspecific febrile illnesses 
(W.J.Koroshetz, R.G.González, 2006). 
PRTMARY LESIONS OF THE CEREBROVASCULAR 
SYSTEM 
CAROTID STENOSIS 
Many stroke patients have atherosclerosis, indicating a link between cardiac 
and cerebrovascular disease. But it is difficult for clinicians to predict the 
likelihood of strok.e using signs and symptoms of heart disease. For instance, 
carotid bruits are more reliably predictive of ischemie heart disease than of 
stroke (W.J.Koroshetz, R.G.González, 2006). 
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PLAQUE 
A carotid plaque's variable composition may affect the associated stroke 
risk. Plaque is often echo dense and calcified, and can be formed by the 
homogenous deposition of cholesterol. Plaque is dangerous not only because 
of its stenotic effects - plaque may rupture or dissect at the atherosclerotic 
wall, showering debris into the bloodstream, leading to multiple embolie 
cerebral infarcts downstream of the plaque. The ruptured, ulcerated plaque 
can also be a source of thrombus formation in that the anticoagulant 
properties ofthe endothelia! surface are locally disrupted. Using transcranial 
Doppler, a number of groups have shown increased frequency of 
microembolic signals in the ipsilateral MCA in the days after symptom onset 
in patients with carotid stenosis. lnflammation in the plaque wall has been 
postulated to influence thrombus fonnation in myocardial infarction (MI) as 
well as stroke. Recent studies have focused on the possibility that infection 
in the plaque contributes to thrombus formation and subsequent stroke or 
MI. Chlamydia particles have been recently discovered in carotid and 
coronary plaques (W.J.Koroshetz, R.G.González, 2006). 
ATHEROSCLEROSIS LEADING TO STROKE 
An atherosclerotic lesion at the origin ofthe ICA can lead to stroke. The first 
pathway is a result of progressive narrowing of the ICA until the sluggish 
blood flow promotes the fonnation of a thrombus at the residua! lumen, 
which results in complete occlusion. The acute occlusion may be 
symptomless if excellent collateral circulation exists along the circle of 
Willis and between leptomeningeal vessels; altematively it may cause a 
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large hemispheric stroke if collaterals are poor. The second pathway, termed 
"artery to artery" embolism, is a common pathway for MCA distribution 
stroke in patients with severe extracranial intemal carotid stenosis. 
Commonly, this occurs at the time of ICA occlusion (W.J.Koroshetz, 
R.G.González, 2006). 
COLLATERAL PATHW A YS IN THE EVENT OF CAROTID STENOSIS 
OR OCCLUSION 
In the pathway shown above (Fig. 12), leptomeningeal collateral blood 
sources traveling over the surface of the brain bring blood from the distal 
ACA branches into the distal MCA branches. This type of leptomeningeal 
collateral flow can also come from the posterior cerebral artery (PCA) 
branches to fill the distal MCA. Flow from the vertebrobasilar system can 
fill the distal ICA and its branches through the posterior communicating 
artery (PCoA). The potential for collateral flow in the case of carotid 
occlusion depends on the vascular anatomy of these altemative pathways. 
When collateral flow is not sufficient, ischemia occurs in the border zone 
(sometimes called "watershed") regions between the ACAIMCA and 
MCAIPCA (W.J.Koroshetz, R.G.González, 2006). 
TRANSIENT NEUROLOGICAL DEFICITS 
Reoccurring transient neurological deficits also occur commonly in patients 
with MCA or intracranial carotid stenosis. These deficits generally last for 
less than 3min and include transient monocular blindness as well as transient 
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hemispheric neurologie deficits. Their pathologic basis is unknown, though 
in some cases of transient monocular blindness there is evidence of low flow 
(the "box car'' appearance ofred cell clumps separated by clear space) in the 
retinal arterioles. The retina may also contain highly refractile cholesterol 
emboli called Hollenhorst plaques. ln many instances of severe carotid 
stenosis or occlusion, the intracranial collateral flow is suffi.cient to perfuse 
the brain and prevent ischemia (W.J.Koroshetz, R.G.González, 2006). 
INTRACRANIAL A THEROSCLEROSIS 
Atherosclerosis can also occur intracranially to cause focal or multifocal 
stenosis in the siphon portion of the ICA, the MCA stem, the branch points 
ofthe major MCA branches, the ACA, Al and A2 branches, the Pl and P2 
segment of the PCA, the distal vertebral artery, the vertebral artery origin, 
the vertebrobasilar junction, and the basilar artery. Microatherosclerotic 
plaques can occur as described above in the proximal portion of the 
penetrator arteries arising from the major vessels at the base of the brain. 
They are not seen in the leptomeningeal vessels over the cortex. 
Atherosclerosis in the intracranial portion of the carotid and in the MCA 
causes multiple strokes in the same vascular territory. It may also cause 
"slow stroke" syndrome, in which there is progressive worsening of focal 
cortical ischemie symptoms over days or weeks. ln addition, the penetrator 
arteries flowing to the deep white matter and striatum originate from the 
MCA stem (Ml) and may be occluded in patients with severe MCA stenosis. 
Atherosclerosis in the intracranial portion ofthe ICA and the MCA is more 
common in African Americans and Asian Americans for unknown reasons. 
Additional common sites for atherosclerotic occlusion include the origin of 
the vertebral artery, the distal vertebral and vertebrobasilar junction, the mid-
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basilar artery, and the proximal PCA. Unlike ICA disease, severe 
atherosclerotic stenosis in the distal intracranial vertebral and basilar arteries 
can cause stroke via thrombotic occlusion of local branches as well as artery-
to-artery embolus to the top ofthe basilar artery or the PCA(s). Low flow in 
the basilar artery can lead to thrombus formation with occlusion of one 
brainstem penetrator vessel after another. Basilar thrombosis is not rare and 
is fatal because brainstem function is completely dependent on this vascular 
supply. Low flow to the basilar artery can also be caused by vertebral 
disease. Sometimes one vertebral artery is smalt and terminates as the 
posterior inferior cerebellar artery, never making the connection to the 
basilar artery. Other times, one vertebral artery is occluded. ln these two 
circumstances, flow-limiting disease in the dominant or remaining vertebral 
artery may then produce basilar ischemia. Thrombus at the site of vertebral 
artery stenosis can also dislodge and cause embolie stroke in the distal 
basilar artery or PCA tenitory. ln patients with left subclavian artery 
occlusion, the left vertebral artery commonly originates distal to the 
occlusion. This can result in the subclavian steal syndrome, in which blood 
flows in a retrograde direction down the vertebral artery to supply the arm. 
This anatomie condition is most frequently asymptomatic, but can result in 
low flow in the basilar artery during arm exercise. In some patients with 
longstanding hypertension there is a dramatic dilatation of the intracranial 
vessels called "dolichoectasia." Basilar artery dolichoectasia can cause 
compression of the brainstem or cranial nerv es. Thrombus can also form in 
these much dilated vessels leading to basilar-branch thrombotic occlusion or 
distal embolie stroke (W.J.Koroshetz, R.G.González, 2006). 
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AORTIC ATHEROSCLEROSIS 
Atherosclerotic disease of the aorta is also likely to increase stroke risk. 
Transesophageal echocardiographic images can show plaque or thrombus on 
the aortic wall with dramatic flapping of a thrombus within the aortic lumen. 
Aortic atherosclerosis is a major cause of stroke during coronary artery 
bypass grafting; when the aortic cross clamp is released~ atherosclerotic 
debris :fills the aorta. Atherosclerotic emboli also occur as complications 
after coronary and aortic angiography due to vessel wall trauma from the 
catheter. So-called cholesterol emboli disease can cause multiple strokes as 
well as joint pain; livedo reticularis skin rash, reduced renal :functio~ and 
seizures. These cholesterol embolie strokes may not be amenable to 
thrombolysis. Type I aortic dissection is one of the most difficult vascular 
lesions to manage in the presence of major stroke. The patient may present 
with chest pain and asymmetric pulses. Stroke may occur in the distribution 
of any major cerebral arteries because the dissection can involve both carotid 
and vertebral origins. Since rupture into the chest or extension of dissection 
into the pericardium or coronary origins is fatal, thrombolysis or 
anticoagulation cannot be used (W.J.Koroshetz, R.G.González, 2006). 
RISK FACTORS FOR A THEROSCLEROSIS 
Hypercholesterolemia, family history of atherosclerotic disease, diabetes~ 
homocysteinemia, elevated apolipoprotein a, hypertension, and smoking are 
all risk factors for generalized atherosclerosis. lnflammatory markers in the 
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plaque and the systemic circulation are currently under study for their role in 
triggering symptoms in patients with atherosclerosis. 
EXTRA-CEREBRAL ARTERY DISSECTION 
Extra-cerebral artery dissection is commonly responsible for stroke in young 
persons, including children. In adults, dissections tear the intima, and blood 
enters the wall of the vessel between the intima and the media. This blood 
causes the vessel wall to balloon outward, and compresses the lumen. If 
stroke results :from this condition, it is most often caused by embolus; a 
thrombus forms at the tear site and is swept up the vessel into the brain. 
Dissection may also cause complete occlusion of the vessel and impair 
cerebral perfusion. The .outwardly distended vessel wall may also compress 
nearby structures. In carotid dissection at the base of the skuli, compression 
palsies of cranial nerves IX, X, XI, and XII are sometimes seen. Carotid 
dissection can also interrupt the sympathetic nerve fibers that surround the 
carotid, caus ing a Homer' s syndrome ptosis and miosis. The dissection site 
can be high up in the neck, often e:xtending to the point where the ICA 
becomes ensheathed in the dura at the entry site into the petrous bone. 
Dissection also occurs in association with redundant looping of the carotid 
artery. Vertebral artery dissection commonly occurs where the vessel passes 
over the C2 lateral process to enter the dura. 
Symptoms: 
Patients with carotid or vertebral dissection commonly present with pain. In 
extracranial carotid dissection the pain is localized to the region above the 
brow in front of the ear, or over the affected carotid. ln vertebral dissection 
the pain is usually in the C2 distribution, ipsilateral posterior neck, and 
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occipital regions. Ex1racranial cerebral artery dissection occurs with 
massive trauma as well as minor neck injuries. It also occurs with seemingly 
trivial incidents, such as a strong cough or sneeze, chiropractic manipulation, 
hyperextension of the neck during hair washing, etc. In some cases, it 
appears to occur without known precipitants.Disorders of collagen such as 
fibromuscular dysplasia, Marfan's syndrome, and type IV Ehle~Danlos 
syndrome are also associated with dissection. Arterial dissection can result 
in the formation of a pseudo-aneurysm. Rupture of dissected vertebral 
arteries into the subarachnoid space is more common in children. Rupture of 
dissected carotid artery pseudo- aneurysms into the neck or nasal sinuses is 
generally rare. Dissection can occur intracranially and, on rare occasions, 
can spread intracranially from a primary e:xtracranial origin. 
PRIMARY CARDIAC ABNORMALITIES 
ATRIAL FffiRILLA TION 
Atrial fibrillation (AF) is a major risk factor for debilitating stroke due to 
embolism. The Framingham Stroke Study estimated that 14% of strokes 
occurred because of AF. The prevalence of AF i s high and increases with 
age, peaking at 8.8% among people over the age of 80 years. The risk of 
stroke in patients with AF also increases with age: as many as 5% of patients 
over 65 with AF suffer embolie stroke. These emboli often originate as a 
mural thrombus, usually harbored by the fibrillating atrium, and more 
specifically the atrial appendage, because of its potential for regions of 
stagnant blood flow. Anticoagulation with warfarin has been shown to 
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decrease stroke risk in elderly patients with AF or younger patients with 
concomitant heart disease, reducing the risk of thrombus formation. In the 
evaluation of the patient with AF who experiences a stroke, it i s important to 
determine whether the prothrombin time is elevated. The risk of warfarin-
associated major hemorrhage, mostly intracranial, is approximately 0.5% per 
year. A hemorrhagic stroke, however, can stili occur with a well-controlled 
prothrombin time. 
MYOCARDIAL INFARCTION 
Myocardial infarction (Ml) commonly causes intraventricular thrombus to 
form on the damaged surface of the endocardium. Acute anterior wall 
infarction with aneurysm formation is especially associated with thrombus 
formation and stroke. Poor left ventricular function and ventricular aneurysm 
is also associated with increased risk of embolie stroke. 
VAL VULAR HEART DISEASE 
Atrial fibrillation with mitral valve disease has long been considered a stroke 
risk factor. Mechanical prosthetic valves are prime sites for thrombus 
formation; therefore, patients with these valves require anticoagulation. 
Bacterial endocarditis can cause stroke as well as intracerebral mycotic 
aneurysms. Inflammatory defects in the vessel wall, when associated with 
systemic thrombolysis and anticoagulation, rupture with subsequent lobar 
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hemorrhage, and precipitate stroke. Nonbacterial, or ''marantic," 
endocarditis is also associated with multiple embolie strokes. This condition 
is most common in patients with mucinous carcinoma and may be associated 
with a low-grade disseminated intravascular coagulation. A nonbacterial 
endocarditis, called Libman-8acks endocarditis, occurs in patients with 
systemic lupus erythematosus (SLE). The role of mitral valve prolapse in 
stroke remains controversial. Strands of filamentous material attached to the 
mitral valve seen by echocardiography have recently been reported as a risk 
factor for embolie stroke. 
PATENT FORAMEN OV ALE 
Patent foramen ovale (PFO) occurs in approximately 27% of the population. 
Though the left-sided pressures are usually higher than those on the right, the 
flow of venous blood toward the foramen ovale can direct some blood to the 
left side ofthe heart. Increases in right-sided pressures, which can occur with 
pulmonary embolism or the Valsalva maneuver, increase blood flow :from 
right to left atrium.PFO has been detected with increased incidence (up to 
40%) in young persons with stroke. It is thought that venous clots in the leg 
or pelvic veins loosen and travel to the right atrium, and then cross to the left 
side of the heart causing embolie stroke. This conclusion is supported when 
stroke occurs in the context of deep vein thrombosis (DVT) or pulmonary 
embolus (PE) in a patient with PFO. 
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CARDIAC MASSES 
Atrial myxoma is a rare atrial tumor that causes multiple emboli of either 
thrombus or myxomatous tissue. When the myxomatous emboli occur from 
the left atrium, they may cause the formation of multiple distal cerebral 
aneurysms with risk ofhemorrhage. Fibroelastoma is a frond-like growth in 
the heart that is also associated with a high stroke risk. 
EMBOLIC STROKE 
THE LOCAL VASCULAR LESION 
The occlusion of an intracerebral vessel causes local changes in the affected 
vessel and its tributaries. There is also a vascular change in the 
microcirculation supplied by these vessels. As an embolus travels toward the 
brain, it is forced into progressively narrower vessels before it lodges in a 
vessel too smalt for it to pass. The initial shape of emboli and their course 
are not well known. Because the major vessels of the Circle of Willis have 
lumen diameters of only 1-2 mm, dangerous clots need not be very large. 
Some clots that have a string shape and curl, like those from a deep vein, 
become temporarily stuck at tums in the vessel, eventually becoming 
compacted into a plug when they finally lodge. The vessel is often distended. 
Symptoms localized to basilar branches sometimes occur in the moments 
before a top of the basilar ischemie syndrome occurs. Called the "basilar 
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scrape," this is thought to result from temporary ischemia caused by the 
embolus as it travels up the vertebral and basilar vessels to the bifurcation at 
the top ofthe basilar artery. Emboli lodge at branch points, such as theT-
like bifurcation of the basilar into two posterior cerebral arteries, and the T-
like bifurcation of the carotid into the ACA and MCA. The fork of the MCA 
stem into the two or three divisions of the MCA is another common lodging 
site for emboli. Small branches coming off the large vessel at these sites will 
be occluded. There are a number of thin penetrator vessels that supply the 
midbrain and the overlying thalamus that are occluded in the top of the 
basilar embolus. The lumen of the anterior choroidal artery is in the distal 
carotid. Coming off the middle cerebral stem are penetrators to the striatum 
and interna! capsule. Ischemia in these vascular territories that have little 
collateral flow channels can quickly lead to infarction as compared to 
ischemia in the cerebral cortex, which can receive blood flow via 
leptomeningeal collaterals. 
MICROVASCULAR CHANGES IN ISCHEMIC BRAlN 
In contrast to the situation in occluded small vessels, the vascular tree distal 
to an occlusion in a main cerebral vessel will not be occluded by the clot. In 
order to keep blood flow at nonnal levels, the distal vascular tree undergoes 
maxima! vasodilatation. This vasodilatation is in part regulated by the action 
of nitric oxide on the vascular wall. Ischemie vasodilatation will attract 
collateral flow to the cortex from other vascular channels through 
leptomeningeal vessels. In the fully dilated bed, the cerebral blood flow will 
be driven by the blood pressure. As blood flow falls in the microvessels 
there is potential for microvascular thrombus formation. The endothelia! 
surface of the microvascular circulation normally has an anticoagulant 
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coating. Under ischemie conditions, it becomes activated to express white 
blood cell adhesion molecules. White blood cells attach to the vessel wall 
and may mediate microvascular injury and microthrombosis. In such a case, 
despite the recanalization of the main feeder vessel, there is ''no reflow"of 
blood to the tissue. This loss of accessibility of the microvasculature to the 
blood pool and decreased cerebral blood volume are closely linked to 
infarction. In animal studies, stroke size is decreased if white blood cell 
counts are reduced or drugs are given to block white cell adhesion. Free 
radical production by the white blood cells is considered an important 
mediator of vessel-wall injury in stroke. Damage to the vessel wall is 
manifested as hemorrhage into the infarct. Hemorrhagic conversion of 
embolie stroke is very common when examined by magnetic resonance 
imaging (MRl) sequences sensitive to magnetic susceptibility of the iron. In 
hemorrhagic conversion there are multiple small hemorrhages in the infarct 
that may not be apparent on CT scan or may be seen as a hazy or stippled 
increase in signal intensity. Large hemorrhages can also occur in the 
infracted tissue. The latter are more common in large strokes that include the 
deep white matter and basal ganglia. As opposed to hemorrhagic conversion, 
which is usually not accompanied by clinical change, the large hematoma in 
the infracted zone is often associated with worsened neurologie deficit. 
These hematomas frequently exert considerable mass e:ffect on adjacent 
brain tissue and can increase intracranial pressure (ICP) and distort midbrain 
and diencephalic structures. Since these hemorrhages more commonly occur 
in the larger strokes, they often compound the mass effect due to ischemie 
edema. Hematoma formation is the major risk of thrombolytic therapy. The 
use of drugs that impair hemostasis (anticoagulants) may increase the 
probability ofbleeding into a vascular territory with an injured vascular wall. 
Hemorrhage occurs when the blood flow and blood pressure are restored in a 
previously ischemie zone. The injured vascular wall is incompetent to with 
stand the hydrostatic pressure and the return of oxygen and white blood cells 
may also intensify the reperfusion injury at the vascular wall. The vascular 
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wall also regulates the flow of large molecules from the vascular space to the 
intercellular space (the so-called blood-brain barrier). ln ischemia, there is 
net movement of water into the brain tissue. This is the basis of the increased 
T2 signal on MRl and the low density on CT in the first few days after 
stroke. At variable times after stroke, contrast imaging studies show that 
large molecules also cross into the brain tissue. The net water movement into 
brain, ischemie edema, can lead to secondary brain injury as a result of 
increased ICP and the distortion of surrounding tissues by the edematous 
mass effect. Mass effect, causing clinical worsening and classical hemiation 
syndromes, is not uncommon in patients with large MCA strokes. 
MCAEMBOLUS 
An embolus to the MCA is common and can cause a catastrophic stroke. It is 
also amenable to rapid therapy. For these reasons, special emphasis is placed 
here on this stroke subtype. As discussed above, carotid stenosis and 
occlusion cause stroke by arteryto- artery embolus into the MCA territory or 
by causing a low-flow state. This gives rise to the clinical syndrome of 
MCA stroke. Distinguishing features of carotid stenosis include the common 
occurrence of multiple stereotypic spells of transient ipsilateral hemispheric 
or monocular dysfunction. ln addition, in carotid stenosis multiple emboli 
may occur over a short period oftime. ln some cases of embolus to the MCA 
from a severely stenotic carotid, the embolus may be less well tolerated and 
the stroke more severe due to the lower perfusion pressure above the carotid 
lesion. Embolus from the carotid to the MCA can also occur from the stump 
of a completely occluded carotid. lf the occlusion is hyperacute, then it is 
often possible to dissolve the fresh clot in the extracerebral carotid with 
urokinase and advance the catheter to treat the intracerebral clot. This can be 
52 1 Pa g e 
followed by angioplasty of the carotid stenosis. However, if the carotid 
occlusion is more chronic, the organized clot extends up from the occlusion 
in the neck intracranially and may prevent passage of the catheter. This will 
preclude intra-arterial thrombolysis ofthe MCA clot. 
BORDERZONE VERSUS EMBOLIC INFARCTIONS 
Carotid stenosis can also cause low-flow stroke when the collateral flow 
from the anterior communicating artery (ACoA), PCoA, and retrograde 
through the ophthalmic artery is insufficient to perfuse the ipsilateral 
hemisphere. Low flow causes symptoms and infarction in the distal cortical 
watershed territory between the distal branches of the ACA, MCA, and 
PCA. The actual boundaries between these territories may shift due to 
increased flow through the ACA or PCA to supply the MCA. The classic 
presentation is called the ''man in the barrel syndrome." The watershed 
ischemia causes dysfunction in the regions for motor control of the proximal 
ann and leg. There may be an aphasia known as "transcortical aphasia" due 
to disconnection of the laterally placed language areas and medial cortex. In 
transcortical aphasia, repetition is relatively preserved. In transcortical motor 
aphasia there is hesitant speech but preserved comprehension. In 
transcortical sensory aphasia, comprehension is more severely impaired than 
speech. Cortical watershed stroke is seen on imaging as a thin strip of 
infarction that runs from the posterior confluence of the MCA, ACA, and 
PCA branches in the posterior parietal cortex extending forward on the upper 
lateral surface of the cerebrum. On axial scans there is a small region of 
stroke on each of the upper cuts; only by mentally stacking the images does 
the examiner appreciate that the lesions are contiguous and form an anterior 
to posterior strip of stroke. The strip overlies the motor areas for control of 
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the proximal leg and arm. A cortical watershed infarction is not entirely 
specific for low flow, because it can also be caused by showers of 
microemboli that lodge in the region of neutral hydrostatic pressure. In 
addition to the cortical watershed, there is also an intemal watershed fonned 
by the junction of the penetrator arteries from the MCA and the 
leptomeningeal cortical vessels that enter the cortex and extend into the 
white matter. This watershed again fonns a strip that lies in the white matter 
just above and lateral to the lateral ventricle. Instead of a strip of contiguous 
stroke the intemal water shed region usually undergoes multiple discrete 
circular or oval shaped strokes that line up in an anterior to posterior strip. 
Intemal watershed infarction may be more specific for low-flow stroke. 
LACUNAR STROKES 
Penetrator vessels come o ff the basilar artery, the middle cere bral stem, and 
the PCA at right angles to the parent vessel. Small-vessel occlusive disease 
is almost entirely related to hypertension and is characterized pathologically 
by lipohyalinosis and fibrinoid necrosis of small 80- to 800-mm penetrator 
vessels. Occlusion of these penetrators causes small infarcts, tenned 
lacunars, in their respective vascular territories, most commonly in the 
caudate, putamen, extemal capsule, intemal capsule, corona radiata, pontine 
tegmentum, and thalamus. Hypertensive hemorrhage occurs in these same 
regions and is due to the same hypertensive changes in the penetrator 
vessels. The deficits caused by these smalt strokes are a function of their 
location. Because the penetrator vessels supply deep white matter tracts as 
they converge in the intemal capsule or brainstem, the consequence of 
lacunar stroke is often related to disconnection of neural circuits. Lacunar 
strokes are especially common in patients who have diabetes in addition to 
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hypertension. Lacunar strokes can cause immediate motor and sensory 
deficits, though many patients recover considerable function in the weeks or 
months following lacunar stroke onset. In the National Institute of 
Neurological Disorders and Stroke Recombinant Tissue Plasminogen 
Activator Stroke Study (NINDS rt-PA Study), 50% ofpatients retumed to a 
normal functional level within 3 months without rt-PA treatment. In the 
group receiving rt-PA, the probability of good recovery increased to 70%. A 
number of clinical syndromes commonly occur dueto lacunar strokes (see 
Tahle 1). However, the clinical symptoms may not be specific for the 
chronic occlusive disease of the small penetrator vessels described above. 
Of special importance is the infarct in a penetrator territory caused by 
disease of the parent vessel. In some cases, the penetrator stroke is only one, 
sometimes the first, of many regions to undergo infarction due to major 
vessel occlusion. In basilar artery occlusive disease, ischemia in the 
distribution of a single penetrator may occur as the "opening shot." On 
succeeding days, the origin of multiple penetrators becomes occluded due to 
the propagation of mural thrombus in the vessel. In addition, atherosclerosis 
in the parent vessel may narrow the lumen at the origin of the penetrators. 
Atherosclerosis may also occur in some of the larger penetrators. Large 
strokes, or giant lacunes, occur as a result of the occlusion of multiple 
penetrators with occlusive disease in the parent vessel. This is particularly 
common in the MCA territory where leptomeningeal collateral flow 
preserves the cortex, but absence of collateral flow to the penetrator territory 
results in infarction. In some cases, showers of small emboli cause penetrator 
strokes as well as cortical strokes. Small emboli may also reach these 
vessels. Chronic meningitis due to tuberculosis or syphilis commonly causes 
stroke in the penetrator territory due to inflammation around the parent 
vessel at the base of the brain with occlusion of the thin penetrators exiting 
through the inflammatory reaction. 
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Clinicallaeunar syndrome and infarct location 
Pure motor hemiparesis involving face, arm, and leg Contralateral posterior limb 
intemal capsule or overlying corona radiata 
Contralateral pontine tegmentum 
Pure unilateral sensory loss involving face, arm, and leg Contralateral thalamus 
Hemiparesis with bomolateral ataxia Contralateral thalamocapsular region 
Upper third ofthe contralateral medial pons 
Dysarthria, clumsy band Contralaterallower third of the medial pons 
Hemisensory loss and homolateral hemiparesis Genu ofthe internal capsule 
Sensory los s around comer of mouth Thalamocapsular region 
and homolateral weakness ofhand 
Tahle lclinical Lacunar Syndrome and Infarct Location (W.J.Koroshetz, 
R.G.González, 2006) 
OTHER CAUSES OF STROKE 
INFLAMMATORY CONDITIONS 
Primary granulomatous angiitis of the central nervous system causes 
progressive ischemie brain injury. Blood vessels ofvarious sizes are affected 
by inflammation and, on occasion, hemorrh.age occurs in addition to stroke. 
Granulomatous angiitis can occur in the MCA ipsilateral to Vl-distribution 
Herpes zoster or in the vertebral after C2-distribution Herpes zoster. The 
cerebrospinal fluid (CSF) often shows signs of inflammation. Diagnosis is 
commonly made after a biopsy of the leptomeningeal vessels demonstrates 
the granulomatous inflammation. When caught in its early stages, treatment 
with cyclophosphamide and/or steroids can reverse the process. Left 
untreated, the disease is usually fata! and causes severe diffuse or multifocal 
brain injury. 
Systemic lupus erythematosus (SLE) has a variety of presentations in the 
nervous system. Stroke-Iike events can occur, along with seizures and 
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encephalopathy dueto a small vessel vasculopathy. A circulating factor that 
increases the partial thrombin time (PTD, so-called lupus anticoagulant or 
anticardiolipin antibody, is associated with arterial thrombosis. A 
nonbacterial endocarditis may be a cause of embolie stroke. 
Temporal arteritis is a giant cell arteritis seen in older adults with an 
elevated erythrocyte sedimentation rate, an elevated :fibrinogen level, and a 
thickened wall of the extracranial carotid branches. Temporal arteritis can 
cause headache, tendemess over the temporal artery, jaw claudication, and 
transient visual loss. It is sometimes associated with polymyalgia 
rheumatica. It occasionally affects the vertebral artery. 
Talrayasu 's arteritis is a giant cell arteritis ofthe large vessels offthe arch of 
the aorta. It can cause occlusive disease in the carotid and the vertebrals, 
leading to stroke. Polyarteritis nodosa has rarely been reported to affect 
intracranial vessels. Sickle cell disease causes extracranial carotid stenosis or 
occlusion. The beta amyloid that is deposited in plaques of patients with 
Alzheimer' s disease can also infiltrate the walls of the small blood vessels 
that supply the cortex. This amyloid angiopathy is a common cause of lobar 
hemorrhage in the elderly, most of whom do not have Alzheimer' s disease. 
Some patients present with transient neurologie de:ficits prior to their 
hemorrhage. Smalt microinfarctions can occur in the cortex, in addition to 
multiple hemorrhages. Hemorrhage is found to occur in those patients who 
have a combination of amyloid deposition in the vessel wall and :fibrinoid 
necrosis of the vessel wall. Amyloid angiopathy is considered a major risk 
factor for intracerebral hemorrhage in patients receiving thrombolytic drugs 
for MI or stroke. Moya-moya disease is an unusual condition causing 
progressive stenosis and occlusion of the interna! carotid and the vessels of 
the Circle of Willis. Recurrent stroke as well as occasional hemorrhage 
characterizes the clinical syndrome. A proliferation of collateral vessels into 
the deep penetrator territory leads to an appearance of a''puff of smoke" on 
direct angiography. 
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VENOUS SINUS THROMBOSIS 
Venous sinus thrombosis can cause focal neurologie deficits, o:ften with 
seizures, headache, and other signs of mised intracranial pressure. Venous 
strokes are frequently hemorrhagic and located in the proximity of the 
occluded sinus- parasagittal in a sagittal sinus thrombosis, temporallobe in a 
transverse sinus thrombosis, and thalamus in a straight sinus thrombosis. 
V enous sinus thrombosis is seen in patients with hypereoagulable state or as 
a consequence ofinfiltration ofthe major sinus by tumor or infection. 
VASOSPASM IN THE SETTING OF SUBARACHNOID 
HEMORRHAGE 
Subarachnoid hemorrhage (SAH) is most commonly caused by rupture of an 
intracranial aneurysm. lt can result in vasospasm that may cause ischemia 
and infarction. Vasospasm dueto SAH is thought to occur in the majority of 
cases of SAH, but is symptomatic in about a third of this population. 
Permanent neurological injury may occur in IOOA. or more. Vasospasm peaks 
around 1 week a:fter SAH, but it can be seen as early as 3 days or as late as 3 
weeks a:fter the initial event. The underlying mechanisms are not understood, 
but vasospasm is clearly related to the amount of blood in the subarachnoid 
space. 
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MIGRAINE 
Epidemiological studies have demonstrated that migraine is associated with 
ischemie stroke independent of other risk factors. The mechanism is 
unknown, but potential factors include vascular hyper-reactivity, and 
sensitivity to or increased amount of vasoactive substances. 
PRIMARY HEMATOLOGie ABNORMALITIES 
Clotting systems disorders that cause systemic bleeding are associated with 
increased risk of intracerebral hemorrhage. Coumadin use is perhaps the 
most common cause of intracerebral hemorrhage, followed by 
thrombocytopenia. Thrombotic thrombocytopenic purpura (TIP) is most 
commonly manifested as ischemie stroke and should be treated by 
emergency plasmapheresis, which can reverse the microvascular thrombosis. 
Hypercoagulable states, such as protein C or S deficiency and Factor V 
Leiden mutation, increase the risk of venous sinus thrombosis. Arterial and 
venous occlusions occur in anticardiolipin syndrome along with fetal 
wasting and livedo reticularis. A hypercoagulable state with venous sinus 
thrombosis commonly occurs in the post-partum period or in severely 
dehydrated patients. 
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HYPERBARIC OXYGEN THERAPY 
Hyperbaric Oxygen Therapy is defined by the Committee on Hyperbaric 
Medicine as " A mode of medical treatment in which the patient is entirely 
enclosed in a pressure chamber and breathes 100% Oxygen at a pressure 
greater than 1 atmosphere absolute (ATA) ". The unit ofPressure is ATA, 1 
ATA is equivalent to 760 mm ofMercury or pressure at sea level. 
The application of HBO depends on the physical properties of gases under 
pressure, specifically, oxygen at pressure greater than 1atm. Oxygen is 
essential in a variety of enzymatic, biochemical, and physiologic interactions 
that promote normal cellular respiration and tissue function. Mono-
oxygenize, intradioxygenase, and interdioxygenase are specific enzymes that 
recruit oxygen as a cofactor to perform required biologie processes. 
Collagen deposition and synthesis depend on an oxygen dependent prolyl-
hydroxylase hydroxylation of proline. Angiogenesis and epithlization are 
also oxygen dependent. 
Over the past 40 years Hyperbaric Oxygen therapy (HBO) has been 
recommended and used in a wide variety of medical conditions, often 
without adequate scientific validation of efficacy or safety. Consequently a 
high degree of medical scepticism had developed regarding its use (Leach R 
M, Rees PJ, Wilmshurst P. , 1998). Over the last two decades, animal 
studies, clinical trials have produced reasonable scientifi.c evidence or well 
validated clinical experience. This has now produced a set of indications for 
which HBO is benefi.cial (Hampson NB. Chairman & Editor., 1999), (Grim 
PS, Gottlieb U, et al. , 1990). This has led to a renaissance of HBO, and 
hyperbaric facilities now form an important part of many hospitals all over 
the world. China leads with 2600 Hyperbaric Centers, Russia: 2000, Japan: 
400, approx 200 in the UK, 400 all over Europe and approx 800 in the US. 
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In Asia: Malaysia 5 centers, Middle East: 1 O, 1 in Srilanka and 1 emerging 
in Bangladesh (Tanm Sahni, S. Hukku, Madhur Jain, Arun Prasad, Rajendra 
Prasad, Kuldeep Singh, 2004). 
In 1999 there were 500 hyperbaric facilities in USA and presently 800 with 
an annual increase in the number of Hyperbaric Centers and increase in 
patients at the rate of 15 and 620 respectively and this sarne rate of growth 
continues (Tibbles PM, Edelsberg J S. , 1996). With the recent approval of 
HBO as treatment for diabetic foot lesions, the above mentioned figures will 
likely double. With this continuing growth all over the world Hyperbaric 
Medicine has found a distinct role in the modem era of evidence based 
medicine. 
THE IDSTORY OF HYPERBARIC OXYGEN THERAPY 
Attempts in the use of increased atmosphere pressure, for medical therapy 
has been around for hundreds of years. V ague accounts of this treatments 
dates back to the fifth century BC. The very first sealed chamber known as a 
DOMICILIUM was belt by Henshaw, a British clergyman as early as 1662. 
He made use of a system of organ bellows and found a way to adjust 
pressure within a sealed chamber. The principle that was used was that acute 
conditions would respond to elevated atmospheric pressures and chronic 
conditions to reduced atmospheric pressure (Henshow, 1664). The 
Domicilum compressed air (21% oxygen) for number conditions including 
inflammation, scurvy, arthritis, and rickets. No physical improvements were 
observed likely due to its low compression (Neumeister, 2005). 
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Thereafter, air-compression devices evolved in appearance and function. In the late 
1700s Priestly discovered oxygen, consequently a pneumatic laboratory 
enriched with oxygen to treat chronic conditions such as leprosy was 
developed (Junod, 1834). In the early 1930s, the JUNOD reported 
improvement in patients with cardiorespiratory disorders bere a compression 
chamber made of copper was used at 2 atm of pressure. These lead to a rapid 
establishment of several "pneumatic institutes" in Europe. These institutes 
used chambers that could reach pressures of 2 or more atm and accommodate a 
capacity of up to 1 O people per session. Pneumatic spas came to North 
America in 1860, with the first compression chamber built in Oshawa, 
Ontario, Canada (Neumeister, 2005). 
By 1878, much knowledge had been gathered about the effects and uses of 
hyperbaric oxygen therapy. It was also discovered that the use of 
compressed air could facilitate other methods. In 1879 a French surgeon 
Fontaine published bis findings on the effects of hyperbaric treatment he 
reported improved patients outcomes due to increased oxygenation and 
decreased postoperative vomiting and cyanosis. Noted where also easier 
reduction of hemiations. Furthermore he told of his mobile hyperbaric 
chambeťs favorable effects on the outcome of surgery. Fontaine created a 
mobile compressed operating suit that took advantage of a basic law of 
physics (Henry's law), which states that the solubility of a gas in a liquid is 
proportional to the pressure of the gas over the solution, provided that no 
chemical reaction occurs. By raising the atmospheric pressure within the 
chamber, Fontaine was able to increase the amount of oxygen carried by the 
patienťs bloodstream during the administration of nitrous oxide anesthesia. 
This prevented blood oxygen levels from falling too low as typically 
happened with surgically acceptable depths of anesthesia (Fontaine, 1879). 
The introduction of therapeutic compression chambers that made used of 
electric power for its operation dates back to 1891 in the US by Coming. 
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Coming. This chamber was used for the treatment of nervous and mental 
aftlictions (Coming, 1891). 
In 1918 during the Spanish tlu epidemie which resulted in more than 
500,000 deaths, many of which were in a cyanotic state. Orville 
Cunningham came across a discovery. He noted that patients with certain 
cardiovascular disorders who dwelled at high altitudes fared less well than 
comparable patients living closer to sea level. During this time Dr 
Cunningham, successfully treated a rather sick resident physician suffering 
from influenza and was near death from lack of oxygen secondary to 
restricted lung function. This subsequently led Dr Cunningham to develop a 
cylindrical hyperbaric chamber approximately 3 meters in diameter by 27 
meters in length, in which he successfully treated numerous conditions with 
remarkable outcomes (Jacobson JH and others. , 1965). This in turn led to 
the reinforcement of the credibility of the compression chamber during 
treatment ofpatients ill dueto influenza (Cunningham, 1927). 
Cunningham's fortunes took another upturn following the recovery of a 
patient affiicted with kidney disease-uremic state. Ascribing his dramatically 
improved health to hyperbaric therapy, the grateful patient built for 
Cunningham a chamber fit for a king. This chamber - built in Kansas City 
in 1921 - was a hollow steel ball of approximately 20 meters in diameter 
and equipped with a smoking lounge, dining facilities, rich carpeting, and 
private quarters (Arago., 1845). Conditions such as hypertension, diabetes, 
syphilis, and cancer were treated bere until 1930, when it met an undignified 
end. Its continued survival depended on demonstrable successes. 
Cunningham postulated that anaerobic bacteria (bacteria preferring low 
oxygen environments) were responsible for cancers, high blood pressure, 
and many other conditions. Based on this, he predicted that all would resolve 
at elevated atmospheric pressures that increase blood oxygen levels. 
Unfortunately, the local medical society did not find the results compelling 
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and closed the hyperbaric hospital for a lack of scientific evidence or merit 
(Cunningham, 1927). 
The promotion ofhyperbaric medicine came again into effect when elevated 
interest in underwater activities arose amongst the military. Studies in the 
1930s suggested that supplementary oxygen could play an important role in 
treating decompression sickness. However, because oxygen could be 
explosive, three decades passed before equipment was developed that could 
safely handle its administration. Oxygen breathed under pressure forcibly 
washes nitrogen from tissues. Treatment protocols using hyperbaric oxygen 
therefore require substantially less time to complete than do those using only 
compressed air. Thus, hyperbaric oxygen remains the frontline instrument in 
the treatment of decompression sickness to date. 
Hyperbaric oxygen frrst entered land-based medicine in the Dutch surgical 
realm with the concept of drenching tissue, which required pressurization of 
the entire operating theater. Dr. I.Boerema, a cardiovascular surgeon also 
thought of as, the father of modern-day hyperbaric medicine, fostered 
therepapeutic hyperbaric medicine by publishing his fmdings on the use of 
hyperbaric oxygen as an aid in cardiopulmonary surgery in 1956. In 
particular for congenital cyanotic disorders such as tetralogy of Fallot and 
transposition of the great vessels as well as for pulmonic stenosis. His 
hypothesis was based on the idea that by saturating the body tissues with 
oxygen, he would be able to extend the tissue survival time when clamping 
the major arteries (Boerema I and others. , 1956). The advent of more 
effective cardiopulmonary bypass techniques means that hyperbaric oxygen 
is no longer used for cardiac surgery. However, his discovery (with his 
colleague, Dr. Brummelkamp) that HBO inhibited the growth of anaerobic 
bacteria, and thus was an effective treatment for gas gangrene is stili saving 
lives even today. In 1961 he subsequently published his fmdings 
(Brummelkamp, 1961 ). At the same time, Boeroma released an article, ''Life 
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without blood," in which he elaborated the successful treatment of fatally 
anemie pigs with volume expansion and pressurized hyperoxgenation, hens 
the flurry of interest in therapeutic hyperbaric medicine (Boerem~ 1960). 
The discovery that Smith and Sharp unlashed in 1962 reported the enormous 
benefits ofHBO in carbon monoxide poisoning (Smith G, Sharp GR, 1962). 
Fueled by early medical successes employing hyperbaric oxygen, the clinical 
community began deploying hyperbaric chambers at additional sites, such as 
at Duke University, New York Mount Sinai Hospital, Presbyterian Hospital 
and Edgeworth Hospital in Chicago, Good Samaritan in Los Angel~ St 
Barnaby Hospital in New Jersey, Harvard Children's Hospital, and St Luke's 
Hospital in Milwaukee, as well as in numerous international sites. Further 
benefits ofhyperbaric medicine where recorded for the following conditions; 
split-thickness skin graft acceptance, tlap survival and salvage, wound re-
epithelization, and acute thermal burns. These studies subsequently lent 
credibility to the therapeutic use of hyperbaric oxygen therapy. Meanwhile, 
the academic community commenced high-profile international meetings, 
and reputable scientific medical bodies, such as the Intemational Congress 
on Hyperbaric Oxygen and the Undersea Medical Society. Through these 
efforts, the fundamental principles governing the physiological effects of 
hyperbaric oxygen were derived, and practical issues pertinent to 
engineering and hyperbaric medicine came to the fore (National Academy of 
Sciences, National Research Council., 1966). 
During the 1970s, the practice of hyperbaric oxygen therapy experienced 
bard times because: 
)> more effective therapies such as cardiac surgery became available, 
)> efforts to use it for various medical conditions proved unsuccessful, 
)> Physicians who were high-profile HBOT advocates damaged its 
reputation and once again tarnishing the credibility ofhyperbaric medicine. 
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However, respectable practices have been de:fined and established through 
further research, the development of textbooks and scholarly joumals, and 
the activities of professional associations such as the Undersea and 
Hyperbaric Medical Society which as a result of the indiscriminate and 
inappropriate use formulated guidelines for the use ofhyperbaric therapy. 
Scientists and researchers working in this field continue to take great 
advantage of the angiogenic properties that occurs during increased oxygen 
gradients as a result of hyperbaric oxygen therapy. They conducted studies 
on subject of wound-healing such as foot wounds from diabetes, radiation 
ulcers and other ischemie wounds and likewise successfully treated them 
with the use ofhyperbaric oxygen therapy. Prospective blinded randomized 
trials and well-executed laboratory studies continue to further defme the role 
ofhyperbaric therapy in medical therapeutics. 
The undersea medical society changed in 1986, and was renamed Undersea 
and Hyperbaric Medical Society, in recognition of advances in hyperbaric 
treatments an approved certification of added competency in undersea 
medicine was issued by the American Board of Medical Specialists. 
Furthennore in 1991 The National Board of Hyperbaric Medicine 
Technology gave its first certification to hyperbaric technicians (Undersea 
and Hyperbaric Medical Society, 1999). 
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PHYSIOLOGICAL BASIS 
The main princi pal underlining the application of hyperbaric oxygen therapy 
is its dependence on the physical properties of gases under pressure, 
specifically that of oxygen at pressure greater than 1 atm ( Bassett BE, 
Bennett PB Hunt TK Ed., 1986). In order to promote physiological cellular 
respiration and tissue functions in a living organism numerous oxygen 
dependent interactions are required. Included among others are bio-
chemical, physiological and enzymatic interactions. Examples of specific 
enzymes that recruit oxygen as a co-factor for the performance of essential 
biologie processes are mono-oxygenize, intradioxygenase and 
interdixoygenase. Similarly, synthesis and deposition of collagen is realized 
by an oxygen-dependent prolylhydroxylase hydroxylation of proline, 
likewise angiogenesis and epithelization. When we normally breathe air (with 
21% 02) at sea level pressure, most tissue needs ofOxygen are met from the 
Oxygen combined to Hb, which is 95 % saturated. 100 ml blood carries 19 
ml 02 combined with Hb and 0.32 ml dissolved in plasma. At this same 
pressure if I 00% 02 i s inspired, 02 combined with Hb increases to a 
maximum of 20 ml and that dissolved in plasma to 2.09 ml. The higher 
pressure during hyperbaric oxygen treatment pushes more oxygen into 
solution. The amount of 02 dissolved in plasma increases to 4.4 mVdl at a 
pressure of2 ATA and to 6.8 mVdl at 3 ATA. This additional 02 in solution 
is almost su:fficient to meet tissue needs without contribution from 02 bound 
to hemoglobinand is responsible for most of the beneficial effects of this 
therapy. 
A review of diving physics and physiology is helpful in understanding the 
clinical applicability of HBOT (more details bellow under mechanism of 
action). Hyperbaric oxygen pressure is expressed in multiples of atmospheric 
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pressure at sea level, where 1 a1m is about 760 mm Hg or 1 kilogram per 
square centimeter (Grim P, Gottlieb U, Boddie A, et al., 1990) (Tibbles P, 
Edelsberg J., 1996). Under normal circumstances at sea level, hemoglobin 
saturation in the arterial system is 97% and venous hemoglobin saturation is 
70%. In representation of a physiologic maximum under normal conditions 
oxygen is loaded in the bloodstream to hemoglobin in which each gram of 
hemoglobin combines with 1.34 cm3 of oxygen to form oxyhemoglobin. 
Moreover, 97, 5% of oxygen is carried in the bloodstream which is 
combined to hemoglobin and the remaining 2.5% is dissolved in plasma. The 
oxygen content can be calculated with the following equations (Camporesi 
EM, MasciaMF, Thom SR, 1996): 
02 Oxygen content = 1.34 mL of - ofHb g 
y f Hb • 
"""8 o 100 cm3 x percent saturation 
Above 200 mL of mercury of pressure, the oxygen dissolved in plasma 
significantly increases. 
This is calculated with the Henry law: 
Dissolved oxygen (vol%) = 0.0031 (mL 02 I mmHg) 
100cm3 
Under normal conditions with good perfusion at rest, tissues require 5-6 mL 
per dL of oxygen this can be dissolved or hemoglobin-bonded oxygen. 
Increasing the pressure to 3 atm increases the blood oxygen ( dissolved 
oxygen not carried by hemoglobin) to 6mL per dL (Sheridan R, Shank E. , 
1999) (Leach RM, Rees PJ, Wilmshurst P., 1998). Likewise the increase in 
pressure reduces the volume of gases in the blood by virtue ofBoyle's law 
(in an enclosed space, the volume of gas is inversely proportionate to the 
pressure exerted ůpon it) (Jain K, 1999) (Kindwall, 1999). When considering 
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the above illustrated oxygen content equation, oxygen content of blood in 
total under hyperbaric pressure can be calculated, it is equal to the oxygen 
content calculation plus the dissolved oxygen content. The average 
metabolic consumption of oxygen by humans at sea level is 6,6cm2/IOO cm2 
of blood. With all this in mind the following conclusion can be drawn: 
conditions in a hyperbaric chamber at pressures of 3atm while breathing 
100% oxygen, the delivered oxygen content in total is more than the above 
stated metabolic requirement, which than leads us to the next conclusion that 
oxygen can be supplied under these conditions even if there is an absence of 
hemoglobin. 
As oxygen is released from hemoglobin, carbon dioxide the byproduct of 
cellular respiration usually bonds with hemoglobin to fonn 
carboxyhemoglobin (200/o) and carried in the blood. Carbon dioxide is 
further transported in the blood stream. in the fonn of bicarbonate (75%) it 
can be dissolved in plasma (5%). According to Haldane effect, the saturation 
ofhemoglobin with carbondioxide is dependent on deoxygenation. When we 
consider the state of hemoglobin under hyperbaric pressure, we notice that it 
remains saturated and therefore the PaC02 may increase. In patients where 
physiological respiratory compensatory mechanisms are present, extra 
carbon dioxide is exhaled and on the contrary, in cases where these 
mechanisms are pathologic, patients may develop significant carbondioxide 
retention as observed in chronic obstructive pulmonary diseases. This 
condition can be enhanced by an increase in the work of breathing 
exacerbated by hyperbaric treatments. Another reason for possible 
respiratory failure in patients who already are compromised with a raise in 
a.irway pressures is the fact that an increase in hyperbaric pressure leads to 
an increase in the work needed for breathing which is dependent on volume 
and pressure. The tahle 5 lists the effect that HBOT has on the CNS. 
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METHOD OF ADMINISTRATION 
In general the delivery of Hyperbaric Oxygen pressure may be administered 
in one of two following chambers; a Monoplaced chamber and Multiplaced 
chamber (Kindwall, 1999) (Jain, 1999). Monoplaced chambers shelters a 
single patient at a given time. The patient is usually placed in the supine 
position the chamber is then pressurized with 1000.4 Oxygen. These 
chambers are used to treat stable patients with chronic medical conditions, 
they are the less-costly option when considering initial setup and operation, 
but presents little or no opportunity for patient intervention during therapy. 
Current chambers intergrades a clear acrylic shell or view port that 
maximizes patient observation. In addition direct communication between 
the patient and the hyperbaric medicine technician or physician is made 
possible by communication device, which are intergraded within the 
chamber. On the contrary multiplaced chambers are designed to 
accommodate and treat many patients at the same time and also in cases 
when treating critically ill patients who require a medical attendant within 
the chamber as the chamber allows for patient-therapist intervention. These 
chambers are pressurized with compressed air that is piped directly from its 
source, while the patient breathes 100% Oxygen through special facemasks, 
endotracheal tubes and or tight fitted Oxygen Hoods. The therapeutic dosage 
may be affected due to the type of chamber in use, multiple chambers for 
example, using face masks or hoods that do not fit perfectly may result in 
dilution of 100 percent oxygen with room air (Jain J. 1999). The treatment 
control panel controls the therapy and monitors the patient during the 
treatment 
A standardized method of the administration of Hyperbaric Oxygen Therapy 
in tenns of duration, frequency and cumulative number of sessions has not 
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yet been found to date. Despite this, most therapy is given at 2 or 3 ATA and 
the average duration of therapy is 60 to 90 minutes. Number of therapies 
may vary from 3-5 for acute conditions to 50-60 for radiation illnesses 
(Sahni T, Singh P, John MJ. , 2003). 
MECHANISM OF ACTION 
A number of laws are applied when explaining the action mechanism of 
hyperbaric medicine. As stated above, in order to fully understand the 
mechanism of action used in hyperbaric medicine and thereby also its 
clinical applicability, a brief review of diving physics and physiology is 
necessary. The physiological bases of hyperbaric medicine are explained 
above. In this section, the two basic laws of physics which directly govems 
the principles of hyperbaric medicine are reviewed. The tahle opposite 
presents a list of pressure equivalents. 
Pressure Equivalents 
1 atmosphere (atm) 
0.1013 megapascals (MPa)* 
1.013247 bar (10m ofsea water) 
33 ft of sea water (FSW) 
34 ft of fresh water (FFW) 
14.7 pounds per square inch (psi) 
760mmHg 
Table 2pressure Equivalents *Preferred 
Si (Intemational System ofUnits) 
Measurement 
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BOYLE'S LAW: States that an inverse relationship exists between the 
pressure and volume of an ideal gas (PV=K). 
The self-contained underwater breathing apparatus (SCUBA) diver is 
exposed to one atmosphere absolute (ATA) at sea level. Every 10 meters or 
33ft of sea water (FSW) adds another atmosphere of pressure. As a diver 
ascends, the gas in her or his lungs expands due to the decreasing pressure. 
As an example, suppose a diver runs out of air at 20 meters of sea water (3 
ATA). Ifthe diver takes one 1ast deep breath and rapidly ascends, the gas in 
the lungs will rapidly expand and potentially rupture the lungs. Air may be 
directly insuftlated into a pulmonary vein, retum to the left si de of the heart, 
and probably travel to the brain, resulting in a cerebral air embolism (WEISS 
AND ROTH, 1994). 
Boyle's law explains not only the pathophysiology of a gas embolism but 
also the rationale for treatment. Recompression in a hyperbaric cbamber 
decreases the size of the bubble through a direct pressure effect; and the use 
of oxygen accelerates nitrogen washout, further decreasing the size of the 
bubble (WEISS AND ROTH, 1994). 
HENRY'S LAW: States that the amount of an ideal gas that is physically 
dissolved in solution is directly proportional to the partial pressure ofthe gas 
(C = n [Pg]). 
HBOT for acute and chronic stroke is based on Henry's Law which can be 
interpreted as follows: the amount of a gas, e.g. oxygen, that is dissolved in 
a liquid solution, e.g. blood, is proportional to the pressure of the gas 
interfacing with that solution. Since nearly 98-99% of hemoglobin in blood 
is saturated with oxygen at sea level all additional oxygen added by 
hyperbaric oxygen exposure is dissolved in the liquid plasma portion of the 
blood. lt is this dissolved oxygen that exerts its drug effect on the pathology 
and pathophysiology in stroke and the other neuropathologies. 
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Another example ofHenry's law at work is observed when large amounts of 
carbon dioxide are dissolved under pressure in soft drink bottles. When the 
cap is suddenly removed, the ambient pressure in the bottle is dmmatically 
reduced. As a result, millions of microscopic bubbles come out of solution 
(WEISS AND ROTH , 1994). 
This example is also applicable, when considering decompression 
sicknesses, in situations where a diver reaches extreme depths, spending 
extended periods of time or maybe ascending too quickly. As a result, 
nitrogen (in divers breathing compressed air) comes out of solution and 
bubbles form in the circulation and tissues. Henry's law also explains the 
rationale for treating decompression sickness in a hyperbaric chamber. 
Recompression in a hyperbaric chamber can re-dissolve the gas bubbles, 
allowing for a more controlled decompression (WEISS AND ROTH , 1994) 
THERAPEUTIC EFFECTS OF HBO IN HUMANS 
Physiologically, hyperoxia has a number of other effects. Hunt and others 
have demonstrated in a number of experimental models and clinical studies 
that elevated tissue wound oxygen tensions result in acceleráted healing and 
more rapid resolution of infection (Jain KK, 1990). 
Hyperoxygenation causes: 
1. Increases angiogenesis, fibroblast proliferation, collagen formation, 
epithelialization, and the ability of white blood cells to kill bacteria. 
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periods of relative hypoxia are needed for maximal angiogenesis and 
stimulation of fibroblasts and macrophages (Hart GB, 1971). Neo-
vascularization in hypoxie areas by augmenting fibroblastic activity 
and capillary growth. This is useful in radiation tissue damage and 
other problem wounds. 
2. lmmune stimulation by restoring WBC function and enhancing their 
phagocytic capabilities and causes vasoconstriction. This may be 
beneficial in a patient with a crush injury and/or compartment 
syndrome. The vasoconstriction decreases edema and compartment 
pressures while hyperoxygenating endangered muscle tissue. 
(Holbach KH, Wassmann H, Hoheluchter KL, et al., 1977) 
Vasoconstriction reduces edema and tissue swelling while ensuring 
adequate Oxygen delivery and is thus useful in acute trauma wounds 
and burns. 
3. Bactericidal for anaerobic organisms & inhibits growth of aerobic 
bacteria at pressures > 1.3 AT A. It Inhibits production of alpha-toxin 
by C Welchii and is synergistic with Aminoglycosides and 
Quinolones. Thus it is life saving in gas gangrene and severe 
necrotizing infections. 
4. At very high oxygen tensions, oxygen has an antitoxin effect with 
respect to carbon monoxide, clostridial, exotoxin, and possibly 
cyanide hydrogen sulfide, and carbon tetrachloride. In addition to a 
general antibacterial effect, hyperoxia is especially effective with 
respect to anaerobic infections (Anderson DC, Bottini AG, Jagiella 
WM, et al., 1991) 
5. Reduces half-life of Carboxyhaemoglobin from 4 to 5 hours to 20 
minutes or less and is the treatment of choice for Carbon Monoxide 
poisoning in fire victims. 
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6. Mechanical effects - direct benefit of increased pressure helps 
reduce bubble size in Air Embolism and Decompression Illnesses 
7. Reactivates "sleeping cells" in the penumbra region around central 
dead neuronal tissue. This is the basis of its use in neurological 
conditions. It also reduces adherence of WBCs to capillary walls and 
maybe useful in acute brain and spinal cord in jury. 
BENEFICIAL EFFECTS OF HBO 
+ HBOT is safe accompanied by very few and minor side effects 
<• Addition of HBO obviates the need for frequent surgical procedures 
-+ promotes healing and early mobilization ofthe patient. 
<• Reduces length of hospitalization and thereby overall treatment and 
rehabilitation costs. 
<• Emerging role in indications which have lifetime disabilities 
ADVERS EFFECTS/ COMPLICATIONS 
Hyperbaric oxygen therapy is safe when used in standard protocols. One of 
the most common si de effects may be slight pain in the ears ( aural 
barotraumas) due to a blocked Eustachian tube. Less commonly, 
pneumothorax and air embolism and transient reversible myopia after 
751 Pa g e 
prolonged HBO therapy is experienced. An occasional patient may be 
claustrophobic. Fire is a realistic hazard but preventable by strict safety 
procedures (Edmonds C, Lowry C, Pennefather J, 1994), (Brenk, 1970). 
, Organ Pathology 
-- ---· ··-····------- ·- -1 
Presentation I 
r---- · r----
i Sinuses I Congestion andlor 
Middle ear 
i occlusion 
I Eustachian tube occluded 
i Failure to equalize l pressure within middle 
ear space 
1 External ear Wax build-up or ear plugs 
occlude canal 
I 
-- -~---- ...... ·--···-·-
I 
Pain, bloody discharge 
Edema, rupture, or 
retraction oftympanic 
membrane 
Hemonbage 
Pain, bleeding 
--r--·--- ··· ----·- .. - _J 
Inner ear Oval or round window i Ataxia, vertigo, tinnitus, 
I 
• GI tract 
Teeth 
Gas embolus 
rupture j hearing loss 
I 
- . · T··--
J Oas in bowels, distention i Vomiting, nausea, 
I on ascent I flatulence, colicky pain 
-----1 --
Infected or restored teeth 1 Tooth pain 
(may harbor gas) 
---. 
Tooth implosion or 
explosi on 
Emergent decompression I Sudden decreased level 
! 
with blocked glottis 
, (extremely rare) 
' 
. of consciousness; 
i hemiplegia, blown popil 
1 i 
·· - -- -· 
TABLE 3 ORGANS affected by barotraumas ( UNDERSEA AND HYPERBARIC 
MEDICAL SOCIETY, 1999) 
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INDICATIONS FOR HYPERBARIC OXYGEN THERAPY 
A. UNIVERSALLY ACCEPTED: 
These indications are supported with peer reviewed proof of efficacy 
Wounds: 
<• Problem, non-healing wounds and ulcers (diabetic, venous etc) 
+ Infective wounds - gas gangrene, refractory osteomyelitis, 
Necrotizing soft tissue infections 
+ Acute traumatic ischemias, crush injuries, compartment syndromes 
<• Compromised skin grafts and flaps 
+ Thermal bums 
On co logy: 
+ Late radiation induced tissue damage and complications due 
to endarteritis 
•:+ Prophylactically adjunctive to therapeutic radiation, for 
preparation of surgery or implant procedures in previously 
irradiated fields 
Primacy Line of Treatment: 
<• Air or gas embolism 
<• Decompression Sickness 
•:• Carbon Monoxide poisoning, smoke inhalation 
Other lndications 
•:• Acute Sensorineural Hearing Loss 
•:• Intracranial Abscesses 
+ Bell's Palsy 
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B. RESEARCH INDICATIONS: 
Role ofHBOT in these indications is being studied in intemational trials 
•:+ HBOT in neurological illnesses - cerebral palsy, stroke, head injury 
•:+ HBOT as a radiosensitiser in Glioblastoma multiform and 
re-irradiation of sqamous cell Ca 
A detailed elaboration of all indications a beyond this publication for further 
information see (Undersea and Hyperbaric Medical Society, 1999). 
INDICATIONS FOR HBOT IN NEUROLOGICAL ILLNESSES 
Cerebrovascular accidents (stroke): The reported rate of improvement is 
400/o to 100%, which i s much higher than the natural rate of recovery. lt 
shows a striking reduction in spasticity possibly due to improved function of 
neurons in affected areas or the brain and secondly to rise of P02 in the 
spastic inactive and hypoxie muscle. Additionally there is an improvement in 
the cognitive and mental performance. The major criticism is that none of 
the reported studies are random controlled. 
Acute traumatic brain injuries: HBO causes reduction of CBF thus reducing 
intracranial tension yet providing concomitant high doses of Oxygen to the 
brain. lt interrupts the cycle of Ischemia, Hypoxia, edema and enzymatic 
derangements. There is improved aerobic metabolism, reduction in lactate 
levels, increase in creatinine phosphate and ATP levels. Elevation of partial 
pressure of Oxygen increases the ditfusion distance, and 02 delivery in 
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abnormal areas is enhanced. However there has to be a responsive cerebral 
circulation. lt is contraindicated when a stage of vasomotor paralysis has 
developed, and must not have fixed and dilated pupils. Most favorable 
results are obtained in patients in mid level Glasgow Coma scales. 
Spinal cord injury: There is evidence that it is useful in Spinal cord traumas 
especially if administered within the first 4 hours and for subsequent 
rehabilitation of Spinal damage patients. 
Cerebral Palsy: Evidence now shows that HBO therapy may dramatically 
improve some CP symptoms - spasticity, vision, hearing, and speech. 
However improvement, if any, will vary from patient to patient. More 
oxygen may help many children with cerebral palsy, but it is NOT a cure. It 
is simply a way of ensuring the most complete recovery possible and must 
be combined with other therapies. 
Bell's palsy: Steroids and surgical decompression are the only treatment 
used currently but results are inconclusive as to their benefit. HBO added to 
other treatment increases the e:fficacy of the treatment and reduces the period 
needed for restoration of com plete function of the damaged nerve. 
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CONTRAINDICATIONS TO HYPERBARIC OXYGEN 
·- -- --~--·-
1 
i Condition 
~-----·------
1 Rationale 
i r--··· -------------- -----·· ·-·-···-·,·-·· .. ---- -· -- ··· 
I 
I 
I Claustrophobia 
I 
!Anxiety 
i 
-- r·--- ·-- -·-····· .... -·····-···· 
-· ·-1 
i Pneumothorax 
' 
History of spontaneous 
' pneumothorax 
Gas emboli, pneumomediastinum 
I 
Pneumoperitoneum 
Tension (pneumothorax), Subcutaneous 
' I emphysema 
I 
) 
----·.-- -
I lncreased lung bleb incidence (pneumothorax) 
I 
I 
r·-·-- .. ..... - ----
' Chronic obstructive pulmonary ; Increased oxygen intolerance 
) 
1 disease i lncreased risk of seizures 
I 
- ------. . - --T - ·- - - - -· ··-
Pneumocystic carinii pneumonia j Questionable fetal teratogen 
I 
I 
i 
I 
-I 
--- ---~--- --- .. ----·-····------------------- -- -----~ 
I Seizure disorders 
I 
; Barotrauma to sinus/ear/lung 
-~~e~-~shold for oxygen-induced seizures -1 · Pregnancy* 
Upper respiratory infection I Increased hemolysis 
i 
------------------ - -- --------,--- --·- -
Hyperthermia 
. Hereditar spherocytosis 
1 Optic neuritis 
~ 
Malignant tumors 
I 
I 
----·r 
I 
i Questionable - lncreased optic nerve pathology 
' 
r - -- --·--- ........ . 
! Questionable - Increased vascularity for tumors 
I 
---------~ - - -· ······· ·- -- --
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i Acidosis 
I 
l orugs 
cis-platinum 
Doxorubicin 
• Bleomycin 
Steroids 
Alcohol 
1 
Aromatic hydrocarbons 
Disulfiram 
, Nicotine 
----- ·-·· 
! Decreased threshold for oxygen seizures 
i 
-- - ······-r··· .. -
i 
I 
Decreased wound healing 
1 Increased free oxygen radicals 
I Pulmonary fibrosis leading to pneumothorax 
Decreased thresbold for oxygen seizure 
I 
i Dehydration (increased risk of decompression 
sickness) 
Spontaneous combustion 
Inhibits superoxide dismutase 
: Decreased seizure threshold 
TABULKA 3 CONTRAINDICA TIONS ( UNDERSEA AND HYPERBARIC MEDICAL 
SOCffiTY, 1999) 
*HBO may be required in pregnancy in situations of carbon monoxide poisoning, cerebral 
gas embolus, decompression sick:ness, or clostridial myonecrosis. 
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SPECIAL PART 
~~=~~~~C~-~---=-"========================================== 
METHODOLOGY 
ADVISORY GROUP 
Technical experts where identified to assist in formulating the research 
questions and identifying relevant databases for the literature search. This 
included a research supervisor, neurologist specializing in stroke, a physician 
with an HBOT practice, a neuro-researcher from the academy of sciences. 
Throughout the project period, we consulted individua} members of the 
expert adviŠOry group (AG) on issues that arose in the course of identifying 
and reviewing the literature. 
SCOPE AND KEY QUESTIONS 
This review addresses the following questions: 
Whieb part does HBOT play in tbe regeneration of damaged tissues 
after aeute isebemie stroke? 
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What is the relationship between HBOT and synaptogenasis in patients 
after stroke? 
In whieh way does HBOT work to improve spastieity (a musele disorder 
eommon in patients after stroke)? 
To identify the patient groups, interventions, and outcomes that should be 
included in the review, we read back ground material from diverse sources 
including textbooks, scientific meeting proceedings, and Web sites. We also 
conducted focus group and interviews to improve our understanding of the 
clinicallogic underlying the rationale for the use of HBOT. In the focus 
group, we identified outcomes of1reatment with HBOT that are important to 
patients and examined whether patients, who have experience with HBOT 
value certain outcomes differently. A broader goal ofthe focus was to better 
understand the main pathophysiologic reactions that brain cells undergo 
during ischemie brain attack. By reviewing the fundamentals of stroke we 
aim to achieve a clear view on the subject in order to recognize the 
therapeutic specificity that hyperbaric oxygen therapy (HBOT) offers. We 
also took a closer look on the basics of HBO, its history, physiological 
aspects, indications, the principals that accompany it. 
CRITERIA FOR CHOSING HYPOTHETIC FOCUS GROUP 
1. Intervention: 
+ Hyperbaric Oxygen Therapy: any 1reatment using 100 percent 
oxygen supplied to a patient inside a hyperbaric chamber that 
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is pressurized to greater than 1 atm; any frequency, duration, 
and total number of treatments. 
2. Population: 
(• Patients with thrombotic stroke, excluding patients with tra.nsient 
ischemie attack (TIA), hemorrhage (e.g., subarachnoid hemorrhage), 
or vasospasm. 
+ Patients with progressive neurologie diseases (i.e., multiple sclerosis, 
Parkinson's disease, Alzheimer's disease, and chronic cerebral 
insufficiency), acute infectious processes (i.e., mucormycosis), 
radiation sensitization of brain tumors, and reports of treating eye 
damage or sudden deafuess were excluded. 
(• The use of HBOT for approved indications such as acute carbon 
monoxide poisoning or acute air embolism was also excluded. 
OUTCOMES 
Articles reporting clinical end points where soughted. We focused on HBOT 
mechanism of action in relation to the pathophysiologic reactions of brain 
cells after ischemie stroke. In addition to that we also focused on the health 
outcomes, including mortality and functional changes. In reviewing articles 
for inclusion in this report, we were particularly interested in studies that 
reported both intermediate measures (physiologic measures, such as 
intracranial pressure, changes in cerebral blood flow or results of imaging 
studies) and health outcomes, to analyses the effective evidence HBOT. 
Hence, we included studies that reported the effect of HBOT on elevated 
intracranial pressure, an intermediate outcome that is currently a main 
determinant of treatment in current clinical practice. 
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DESIGN 
•) We included studies of both animals and human subjects that 
reported original data 
(• We used the algorithm in Chart 1 to classify the design of studies. All 
of the study designs in the :figure were included in the review except 
for non-comparative studí es ( e.g., case reports ). 
•:• Before-after or time-series studies with no control group were 
included. 
LITERATURE SEARCH STRATEGY 
We searched a broad range of databases to identify published and 
unpublished studies ofthe effectiveness and hanns ofHBOT in patients with 
stroke. Each database initially was searched from its starting date to 
November 2007. 
The Databases We Searched Were: 
MEDLINE 
}> Premed LINE 
EMBASE 
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)o CJNAHL (Cumulative Index to Nursing & Allied Health) 
)o Cochrane Database of Systematic Reviews 
~ DARE (Database of Abstracts ofReviews ofEffectiveness) 
~ MANTIS (Manual, Alternative and Natural Therapy) 
> Health Technology Assessment Database 
> The Undersea & Hyperbaric Medical Society: a large bibliographic 
database (30,000 records ), http://www.uhms.org/library .htm 
~ The Database ofRandomized Controlled Trials In Hyperbaric 
Medicine, http://hboevidence.com/ 
> European Underwater and Baromedical Society, 
http://www.eubs.org/ 
> Intemational Congress on Hyperbaric Medicine, 
http:/ /www.ichm.net/ 
Hand Searches: The references of all included papers were hand searched. 
In addition, independently conducted hand searches of the references from 
the Acute ischemie stroke and imaging, (Aneesh B. Singhal, Eng H. 
Lo, Turgay Dalkara, Michael A.Moskowitz, 2006) Textbook oj Hyperbaric 
Medicine (Jain K, 1999) Merck-manuale ofmedicin (Mark H. Beers, 2003). 
Update literature searching of the electronic databases MEDLINE, 
PreMEDLINE, EMBASE, CINAHL, the Cochrane Library, and the Health 
Technology Assessment Database was completed on August 2007, using the 
same search strategy as used for the initial searches. Finally, a supplemental 
search of MEDLINE, PreMEDLINE, and EMBASE was conducted in 
October 2007. 
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ASSESSMENT OF PAPERS FOR ELIGffiiLITY 
A reviewer (TJ) independently assessed each title and abstract located 
through the literature searches for relevance to the review, based on the 
intervention, population, outcome, and study design criteria listed above. 
Due to time constraints, only studies originally published in the English 
language were considered for review. Retrieved where full- text article, 
report, or meeting abstract of all citations that met the eligibility criteria. 
Independently, the eligibility criteria where reapplied to these materials. 
DATA EXTRACTION 
Extraction of data from studies was performed by the reviewer. Each study 
was assessed for quality using predetermined criteria. An overall assessment 
of each body of literature was made based on the interna! and extemal 
validity, and consistency and coherence ofthe results of studies. 
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ASSESSMENT OF STUDY VALIDITY 
All trials were assessed using a list of items indicating components of 
intemal validity in a standardized fashion, based on validity checklists 
developed at the National Health Service Centre for Reviews and 
Dissemination and by the US Preventive Services Task Force 
(Dissemination, 2001). 
Intemal validity: Indicates the level of confidence we have in the accuracy 
(validity) and reliability (or reproducibility) ofthe results ofthe study. The 
intemal validity of a study is assessed based on criteria set for a specific 
study design. In this way, an observational study would not be judged by 
criteria for randomized controlled trials (RCTs), but rather by criteria that 
apply to-and can be met by-a good-quality observational study. For RCTs 
and nonrandomized controlled trials, the items assessed for intemal validity 
were randomizationlallocation concealment ( e.g., randomization and 
concealment procedures, stratification), baseline comparability of groups, 
timing of baseline measures, intervention, outcome measures, timing of 
follow-up measurements (long enough to assess effects), loss to follow-up, 
handling of dropouts or missing data, masking, statistical analysis (if any), 
and general reviewer comments. The rationale for selecting these criteria is 
as follows: 
•!• Methods used to ensure comparable groups at baseline. 
Some methods of allocating subjects to treatment and control groups are 
more likely to prevent bias and to result in groups that are comparable at 
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baseline. Randomization, the best method to allocate patients to groups, is 
most effective if it is concealed. 
•:• Baseline eomparabllity of groups. 
The purpose of randomization is to distribute prognostic characteristics 
equally in the treatment and control groups. Effective randomization 
distributes known as well as unknown prognostic factors in an unbiased 
manner. We judged studies on how thoroughly they reported baseline 
characteristics k:nown to affect prognosis and on whether there were baseline 
differences between the groups. When the method used to conceal allocation 
is inadequate or is not described, such differences may suggest that 
randomization was subverted or carried out incorrectly. 
<• Use of validated outcome measures. 
The use of validated, reliable outcome measures prevents based on the part 
of persons who assess outcomes. The use of measures that have not been 
shown to be valid and reliable reduces confidence that the findings are 
accurate. 
•:• Masking of outcome assessment. 
The investigators who judge whether the patients have improved should not 
be aware of which patients received the treatment. This benefit of the 
treatment can influence an observer' s assessment of a patienť s condition. 
•:• Stable baseline. 
A before-after treatment study or a time series study relies on the premise 
that the results after treatment are better than could be expected with 
standard medical care and the passing of time. For a reader to accept this 
premise, the study must describe thoroughly the baseline condition of the 
patients, other aspects of care management, the degree of social support, and 
any other factor that might predict the outcome. The baseline condition of 
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the patients must be established to be stable; otherwise, changes seen cannot 
be distinguished :from an evolving clinical picture. Omission of even one 
characteristic that could have accounted for the results raises doubt about 
whether it was really the treatment that is responsible. The baseline 
assessments should be timed in a manner that is appropriate to the study's 
circumstances. 
+ Use of valid outeome measures and masking of outeome 
assessment. 
Each study was assigned an overall rating (good, fair or poor) according to 
the US Preventive Services Task Force methods. The definitions ofthe three 
rating categories for these types of studies are as follows. 
Good: Comparable groups assembled initially (adequate randomization and 
concealment, and potential confounders distributed equally among groups) 
and maintained throughout the study; follow up at least 80 percent; reliable 
and valid measurement instruments applied equally to the groups; outcome 
assessment masked; interventions defmed clearly; all important outcomes 
considered; appropriate attention to confounders in analysis; for RCTs, 
intention-to-treat analysis. 
Fair: Generally comparable groups assembled initially (inadequate or 
unstated randomization and concealment methods) but some question 
remains whether some (although not major) differences occurred with 
follow-up; measurement instruments acceptable (although not the best) and 
generally applied equally; outcome assessment masked; some, but not all 
important outcomes considered; appropriate attention to some, but not all 
potential confounders; for RCTs, intention-to-treat analysis. 
Poor: Groups assembled initially not close to being comparable or not 
maintained throughout the study; measurement instruments unreliable or 
invalid or not applied equally among groups; outcome assessment not 
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masked; key confounders given little or no attention, for RCTs, no intention-
to-treat analysis. 
The discussion of results and conclusions in this report is based on the 
analysis of information extracted from the above mentioned text books as 
well as good- and fair-quality studies. Results of good-quality studies have a 
high likelihood of being both valid and reliable. Fair-quality studies have 
important but not fatal flaws in their design or conduct The category of fair 
is broad, with some studies that are probably valid and others that are 
unlikely to be valid, depending on the specific flaws found and their 
severity. The inadequacies found in poor-quality studies make the results 
unreliable. 
Extemal validity: Extemal validity refers to the applicability of the results of 
the study to clinical practice. 
I. The investigators should describe the criteria used to identify eligible 
subjects for the study. 
II. They should report the numbers of patients who were considered for 
inclusion in the study, the number that met the eligibility criteria, and 
the number that actually entered the study. 
III. They should report the age range, the severity of disease or disability, 
the prevalence of comorbid conditions, and other sample 
characteristics that would enable a clinician to assess the applicability 
of the results to the patient population for which the intervention is 
intended. 
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EVIDENCE 
The analyses of individual studies reviewed for quality and consistent 
evidence for each key question is based on the interna} and external validity. 
An analysis of whether the body of evidence is sufficient to provide a clear 
answer to the key questions was undertaken. 
SYNTHESIS OF RESULTS 
Results of data extraction and assessment of study validity are presented 
bellow as a narrative description. 
Studies used: The literature searches, both electronic and by band, 
identified over 600 references relating to HBOT and brain injury, 
pathophysiologic reactions of brain cells after ischemie stroke and stroke as 
a whole. These references/abstracts were assessed against the inclusion 
criteria and I 00 full papers where obtained. Upon examination of the full 
papers, 40 were excluded, because they did not meet the inclusion criteria. 
Sixty studies focused more on traumatic brain injury and cerebral palsy and 
had no reports of ischemie stroke among them were also animal studies, and 
the rest were irretrievable. In total 34 studies met inclusion criteria (5 
controlled trials, 17 observational studies and 12 abstract only/conference 
proceeding) most of which are used throughout this report. 
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The review of studies leads to the conclusion that HBOT is beneficial in 
acute global ischemic/anoxia regardless of treating pressure, frequency, 
duration, number of treatm.ents or time to onset of HBOT post insult. The 
best available evidence found shows benefit :from HBOT for stroke. Most 
observational studies reported good, and sometimes dramatic, results. 
Therefore, conclusions about the effectiveness of HBOT for stroke can be 
drawn :from this body of evidence. 
Human clinical studies: The human HBOT experience in cerebral 
ischemia is extensive, complicated and spread across multiple medical 
conditions. Despite the heterogeneous group of studies, the data shows a 
beneficial effect of HBOT, especially in the large series. Five controlled 
trials examined the effect of HBOT in patients with stroke. Four of these 
were randomized (Nighoghossian N, Trouillas P, Adeleine P,et al., 1995) 
(Anderson DC, Bottini AG, Jagiella WM, et al., 1991) (Samo JE, Rusk HA, 
Diller L, et al. , 1972) (Samo MT, Samo JE, Diller L. , v) (Rusyniak DE, 
Kirk MA, May ID, et al. , 2003). One study was non-randomized 
(Marroni.A, 1987). The number of patients ranged :from 32 to 80. Strokes 
were described as ischemie, (Nighoghossian N, Trouillas P, Adeleine P,et 
al., 1995), (Samo JE, Rusk HA, Diller L, et al., 1972), (Rusyniak DE, Kirk 
MA, May ID, et al. , 2003) thrombotic, (Marroni.A, 1987) or vascular. 
(Samo MT, Samo JE, Diller L.) Two trials included only acute patients who 
were within 24 hours of the onset of their stroke, another enrolled patients 
within 2 weeks of onset another enrolled only patients who were at least 2 
months past their stroke (range 2 to 172 months, average 29.2 months) and 
were no longer receiving any therapy or rehabilitation, and the last included 
patients at least 3 months post-stroke (range 3-108 months). HBOT protocols 
varied. The dose was either 1.5 to 2.5 atm, and there was significant 
variation in the number and duration of treatm.ents. The duration of each 
session ranged :from 40 to 60 minutes, and the number of treatments ranged 
:from a single session to 30. Monoplaced chambers were used in three studies 
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and multiplaced chambers in two studies. Control groups were active in the 
randomized controlled trials; three matched the pressure of the treatment 
group but used room air instead of 100 percent oxygen and one used 100 
percent oxygen with 1.14 atm pressure. One added occupational and 
physical therapy to the regimen in both control and treatment group patients. 
The non-randomized controlled trial assigned 80 stroke patients to eight 
comparison groups with combinations of in-water or "dry" physical therapy; 
HBOT at different doses (1.5 or 2.0 atm); both HBOT and physical therapy; 
or no treatment. Patients were assigned to treatment group based on which 
group had an open position at the time they were assigned. In two of the 
randomized trials, both patients and examiners were masked to treatment 
assignment. In the other two, the title describes the study as double-blind, 
but there is no mention in the text about masking of outcome assessors (the 
patients received sham treatments). In the non-randomized controlled trial, 
the examiner, but not the patient, was masked to treatment assignment. One 
study reported outcomes only immediately following a single HBOT 
treatment, two measured outcomes at various points over 1 year, and two 
followed patients for 3 months. 
Randomized controlled trial, Nighoghossian, Trouillas, et aL (1995), 
(Nighoghossian N, Trouillas P, Adeleine P,et al., 1995) enrolled 34 patients 
within 24 hours of the onset of their stroke. Twenty-seven (79 percent) 
patients completed the study. When the mean neurological scores of the 
groups were compared, patients who received 1 O HBOT treatments had 
significantly higher scores at 12 months on two of the three scales used 
(Orgogozo scale and Trouillas scale) compared to patients who were 
assigned to the control group. 
Controlled study, Marroni et al. (1987), was a non-randomized trial that 
used eight different treatment regimens combining HBOT with in-water or 
dry physical therapy compared to no treatment or in-water physical therapy 
alone (no HBOT) (Marroni.A, 1987) The number of patients in each 
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treatment group ranged from 7 to 12; all were stable and were no longer 
receiving any therapy or rehabilitation. Mean outcome measure scores were 
plotted for each group. A:fter 60 days, the groups of patients treated with 
HBOT improved by 1 and 1.8 degrees on the Kurtzke functional scale (a 
scale measuring walking ability and other abilities in patients with multiple 
sclerosis), while control groups had no improvement. Groups receiving 
HBOT plus physical therapy improved more, and the in-water HBOT group 
achieved the largest improvement. Patients were also evaluated on the 
Neuromotor Disabilities Evaluation Scale. This invalidated scale, developed 
by the study authors, measures 1 O groups of limb and system function ( e.g., 
finger and hand function, muscular strength, walking ability) on a scale 
ranging from 17 (best) to 111 (worst). Over a 3-month evaluation period, 
mean scores in the dry HBOT groups improved by 3.1 to 3.8 degrees, and 
patients in control groups improved 1 degree. There were no di:fferences 
among these groups based on concurrent physical therapy or HBOT dose 
(1.5 or 2.0 atm). The groups receiving HBOT and concurrent in- water 
physical therapy improved by 7.7 degrees (1.5 atm) and 11.6 degrees (2.0 
atm). 
There are 17 observational studies of HBOT in patients with stroke. Nine of 
these are before-after studies, (Y.Imai, 1974) (Shn-rong, 1995), (Heyman A, 
Saltzman HA, Whalen RE. , 1966) (KK., 1989) (W-R., March 1-4, 1987,) 
(Noguchi T, Itoh N, Aoyagi M, et al., 1983) (D.Steenblock, 1998; Tsuro M, 
Nakagaway Y, Kitaoika K, et al., 1983; Neubauer RA, End E, 1980)seven 
are time series that measured outcomes at several points before and after 
treatment, (Hart GB, 1971) (Holbach KH, Wassmann H, Hoheluchter KL, et 
al., 1977) (Holbach KH, Wassmann H, Bonatelli AP. , 1977.) (Jain KK, 
1990) (JP., 1981) (Saltzman HA, Anderson B, Jr., Whalen RE, et al., 1965) 
(W assmann H, 1986. ), and one was a retrospective comparison of cohorts 
from two di:fferent hospitals (Pilotti L, 1991 ). The number of patients in 
these studies ranged from 18 to 490. HBOT treatment protocols were o:ften 
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adjusted according to the patienťs condition, so they were not standardized 
either within or between studies. In general, the usual dose was between 1.5 
and 2.0 atm. Duration ranged from 30 to 90 minutes, with most reporting 
about 15 treatments, although there was a wide range. Two studies reported 
mortality rates; three measured grip strength with a dynamometer; one 
performed a mental status examination, two-point discrimination, and 
repetitive thumb/finger movements; two measured spasticity on a five-point 
scale; and one measured 33 different functions of cognition and motor 
ability. One study used a scoring system that included one standard test to 
measure memory (Bender-Gestalt Memory Test), but the other components 
of the score were not validated or well described. In three studies (Y .Imai, 
1974), (Holbach KH, Wassmann H, Bonatelli AP. , 1977.) (Jain KK, 1990), 
outcomes were measured at the conclusion of HBOT treatment. Since the 
duration of treatment varied according to patient response, the timing of 
these follow-up measures also varied. Others followed up patients for 6 
weeks, (Holbach KH, Wassmann H, Hoheluchter KL, et al., 1977) every 3 
months for 1 year, (Jain KK, Klausenbach F, Fischer B., 1989 (June 6-11) at 
6 and 12 months after treatm.ent, (Shn-rong, 1995), and 4.5 years after 
treatment (D.Steenblock, 1998; Tsuro M, Nakagaway Y, Kitaoika K, et al., 
1983; Neubauer RA, End E, 1980). As a group, the observational studies 
reported that between 20 and 83 percent of selected patients with stroke 
improved after HBOT therapy 
Twelve studies of HBOT in stroke reported their results only in meeting 
abstracts. Two were controlled trials. Only one reported detailed inclusion 
criteria. One included subjects with other diagnoses in addition to stroke 
( chronic traumatic, hypoxie, and anoxic brain injuries) and did not report 
outcomes in stroke patients separately. One included mainly patients in 
critical condition in a coma. The number ofpatients ranged from 4 to 140. 
Doses ranged from 1.5 to 3.0 atm, duration from 40 to 90 minutes, and 
number of treatments from 1 to 80. Two studies did not report the HBOT 
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protocol used. One of the controlled trials used a Neurological Recovery 
Score (improvement at 12 months HBOT vs. control, p = 0.031); the other 
reported recurrent stroke or TIA (4.8 percent TIA in HBOT vs. 5.9 percent 
stroke in control, p not given). Two uncontrolled studies reported 
observations or results of unspecified neurological examinations. One stated 
that 100 percent of 18 patients with chronic traumatic, ischemie, hypoxie, 
and anoxic brain injuries showed motor, behavioral, personality or cognitive 
gains by 40 treatments. In another, 80 percent of 140 patients with ischemie 
stroke improved. The other did not report the proportion of patients who 
improved, but reported that "nearly all11 patients who responded favorably to 
HBOT showed a positive response to extra- intracranial arterial bypass 
surgery. Other uncontrolled studies measured band grip and spasticity143 
(improvement in all four patients), recovery of consciousness (17 percent of 
six patients regained consciousness), and short-term memory quotient 
(memory quotient improved significantly from baseline, p < 0.001). 
600 titles and abstructs 
identified 
500 excluded out oftopic 40 excluded did not meet inclusion critera 
60 
braininjmy 
stroke 
100 :fu1l papers obtained 
Chart 1 HBOT Literature Search Reuslt 
22 studies inchred 
stroke 
S controlled studies 
17 observational studies 
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DISCUSSION 
In this section an analysis of data as well as a detailed discussion will be 
undertak:en. 
The core and penumbra concept, can guide us in understanding patient 
management. According to (W.J.Koroshetz, R.G.González, 2006) the core 
is the irreversible necrotic region and the penumbra is the region ofthe brain 
surrounding the necrotic area ( core) this area is underperfused and is in 
danger of in:fracting. Due to the :fragile state of the penumbra, there might be 
a probability that early intensive (physically stressful) physical therapeutic 
intervention might lead to a progression of irreversibly damaged tissue in the 
penumbra, resulting in a deterioration of patienť s state. It is also well known 
that in patients with cardiovascular diseases a blood supply that is adequate 
at rest may be inadequate when cardiac demands are increased by exercise or 
other forms of stress. Increase in stress triggers the release of stress 
hormones, excessive corticosteroids and catecholamines produced at these 
times affects the organism largely. Stress hormones have anti-angiogenic 
properties and accelerate the production of :free radicals and lipid 
peroxidation in blood vessels, all of which will have a detrimental effect on 
newly forming and :fragile capillaries. Hossmann 1994 supports this by his 
elaboration of the importance of decreasing metabolic work load in 
penumbra regions for the improvement of ischemie ressistance in stroke. 
lncrease in stress might also result in an overall increased in blood pressure. 
Hypertension according to (W.J.Koroshetz, R.G.González, 2006) is the most 
significant risk factor for stroke. He furt:her elaborates that, "elevation in 
blood pressure plays a large role in the development of vascular diseases for 
example, cerebrovascular arteries as well as small vessel occlusion". 
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With this in mind, clinically important questions arise. An example may be, 
whether intensive (physically stressful) physical therapeutic intervention in 
acute periods leads to stroke risk factors? Other questions regarding optima! 
physical therapy, initiation time as well as :frequency, however has only 
rarely or not been address from this point ofview so far. Might undertaking 
light forms ofphysical therapy, several times a day and gradually increasing 
in intensity with at a constant :frequency be the answer for the ultimate 
outcomes? Thus decreasing the probability of penumbra infarction and the 
resulting deterioration of patienť s state? 
Cerebral ischemia is among the most common pathophysiologic condition 
involving the centra! nervous system. lt is understood as a result of a focal 
perfusion deficit in an area supplied by brain artery, which can be either 
reversible or permanent. The perfusion deficit is commonly a result of 
arterio-arteriolar or cardiac embolus or the thrombotic occlusion of a brain 
artery. Symptoms of ischemie stroke include hemiparesis, aphasia and 
visual impairments depending on the affected vascular territory (Dirngl 
U.1999). 
An understanding of stroke pathophysiology is responsible for the major 
breakthroughs in developing new therapeutic strategies. Recently several 
trial assesing the usage of neuroprotective drugs, in stroke patients where 
undertaken without particular success. Despite this there is an ever growing 
availability of new promising therapeutic options. One such option is 
hyperbaric oxygen therapy. HBOT has been suggested as a neuroprotective 
adjuvant andlor therapeutic option for the treatment of acute focal cerebral 
ischemia (see section on HBOT). 
Recently, great alternations with regards to the focal point of the 
pathophysiological changes during stroke have occurred. The shift is mainly 
from the earlier focus on blood flow and metabolism to the biochemical and 
cellular mechanisms of stroke pathophysiology. In addition to this, 
molecular and genetic aspects have also gained particular attention. 
991 Pa g e 
With this in mind it is clear that for a better understanding of the 
pathophysiology of focal cerebral ischemia, mechanisms such as cellular, 
molecular, circulatory as well as metabolic mechanisms should be put into 
greater consideration. This knowledge can lead to affective therapeutic 
strategies and possibly the prevention of focal cerebral ischemie 
consequences (Hossmann KA 1994). 
For many years cerebral ischemia has been thought to release glutamate 
from the hypoxie, damaged cells and this glutamate was thought to 
potentiate and propagate the initial hypoxie damage. The recent explanation 
is also based on hypoxie glutamate-mediated injury, but caused by peri-
infarct spreading depression-like depolarization. (Hossmann KA 1994) 
supports this concept. He states that glutamate-mediated injuries are caused 
by peri-infarct spreading depression-like depolarizations. These irregular 
depolarizations are thought to initiate or worsen hypoxie episodes and cause 
a :further suppression in protein synthesis. These depolarization also initiate 
gradual deterioration in energy metabolism and a progression of irreversibly 
damaged tissue into the penumbra zone (see chapter no basic 
pathophysiology). Thus "interventions to improve ischemie resistance should 
therefore aim at improving the oxygen supply or reducing the metabolic 
work load the penumbra region." 
Scientific evidence suggests that, a complex sequence of pathophysiological 
event occurs in stroke. These pathophysiologc events involve excitotoxicity, 
peri-infarct depoloarization, inflamation and programed cell death (see fig. 
2). With this model at band, it is apparent that focal cerebral ischaemic 
therapeutic strategies can be targeted to specific mechanisms that occur at 
specific points in time. Drugs such as glutamate receptor antagonists for 
instance, says (lalbeit), "should be given right after the initial symptoms, for 
its excitotoxic interfering character, where as other drugs such as those 
aimed at inflammation or apoptosis may have an extended time frame and a 
smaller overal! effect". 
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The contributions of non-neuronal cells and in particular glial cells in stroke 
pathophysiology, regeneration and repair are increasingly becoming 
appreciated. Due to the fact that these contributions of glial cells have only 
recently come into focus, scientisťs knowledge in this subject is patchy. 
Nevertheless, evidence suggests that glial cells are the major contributors to 
tissue damage and repair after focal cerebral ischemia (Dirngl U.1999). 
A focal point that recently captured the minds of researchers in the field of 
cerebral ischemia is the concept that elaborates endogenous neuroprotective 
mechanisms (see Fig.2). This concept describes the final infarct as a result 
of a ,,struggle" between protection and destruction. Several experiments on 
animals have been conducted with the aim of further elaborating these 
endogenous protective signaling cascades. The results indicated positive 
outcomes, particularly the protection of the brain against stroke by boosting 
these neuroprotective mechanisms (Dimgl U .1999). The first clinical trials 
aiming at the induction of primarily endogenous neuroprotection ( e.g. 
erythropoeitin) are in progress. 
In general when venturing into brain physiology and pathophysiology a very 
close interaction between neuronal and non-neuronal elements is observed. 
(Dimgll999), states that, "stroke results in the infarction of brain tissue, 
called pannecrosis, (the death of all cellular elements in a given tissue 
volume) ". lt is therefore important to understand, the role that all neuronal 
and non-neuronal cells (especially glial cells) play in the destructive as well 
as protective cascades, evolving in focally ischemie or reperfused brain ( see 
tahle 7). 
Scientific results show that ischemie penumbra is a dynamic process of 
impaired perfusion and metabolism. This impairment may eventually 
propagate with time from the center of ischemia to neighboring tissues. 
Enhancing blood tlow to these areas resulted in the prevention of the spread 
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of cerebral infarction (Heiss, WD, Graf, R 1994). This cou1d help in 
selecting the appropriate thera.peutic interventions in patient after stroke. 
Evidence indicates a reduction in the number of perfused capillaries in the 
penumbra. This loss of capillary perfusion is probably the result of a 
combination of changes that occur in the terminal capillary bed in acute 
ischemie processes. Due to the constrictive and restrictive changes, created 
by the ischemie process, red blood cells are no longer able to pass though 
ischemie and post-ischemie capillaries. Plasma, on the other has been shown 
to reach all ischemie and post-ischemie capillaries, and is able to pass 
through these capillaries (Hossmann 1993). HBOT makes use of this 
advantage that blood plasma offers. One of the mechanisms of action of 
hyperbaric oxygen is to increase the oxygen solubility in blood plasma. It is 
possible to dissolve sufficient oxygen (i.e. 6 vol% in plasma) to meet the 
oxygen needs ofthe brain (K.K. Jain, 1996). Therefore in the acute stroke 
patient, the use of hyperbaric oxygen is able to provide oxygen to ischemie 
neurons and to keep them alive while either endogenous or exogenous 
fibrinolytic mechanisms are brought to bear on the cerebral thrombosis that 
is causing the ischemia. This results in the salvage of the ischemie penumbra 
to a degree impossible with any other therapy. 
Literature and clinical experience predicts that between 80 to 90 percent of 
stroke patients will be helped by hyperbaric oxygen. lnjury to the brain 
causes blood vessels to be damaged or destroyed. The tissue that surrounds 
the area of outright necrosis has had its circulation compromised and may be 
only receiving a fraction of the blood flow and oxygen that it needs for 
optimum health. Thus a disruption in structure creates immediately a change 
( decrease) in function. This decrease in function remains for months or years 
and the neurons in these areas are said to be in "hibernation" or "sleeping". 
Hyperbaric oxygen treatments when given daily stimulate a process called 
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angiogenesis. New blood vessels form in the vicinity of the damaged tissues 
as a result of certain chemical signals (e.g. angiogenin) that are produced by 
the newly re-energized neurons, endothelia! cells and macrophages and are 
then secreted into the surrounding tissues. These signals stimulate new blood 
vessels which slowly reconnect to the damaged tissues and within 60 days of 
daily treatments, the "sleeping" neurons wake up and resume their normal 
functions as the proper structures retum back in place. The hyperbaric 
oxygen induced blood vessel repair results in a permanent structural change 
in the blood vessels that re-supply the previously damaged and 
nonfunctioning nerve tissue which was occurring due to diminished and 
inadequate blood flow. These new blood vessels improve the blood flow and 
oxygen delivery to the damaged brain tissues. This results in permanent 
improvements of stroke. Clinically, what you see is the retum to life of a 
previously paralyzed and useless limb or limbs, improvement in swallowing, 
speech, thinking ( cognition), memory, etc. Quite obviously not all of the 
disabilities disappear since there was a centra! core of dead tissue that cannot 
be revived. However, after the two months of therapy, these people may 
continue to improve for at least two years after their treatment with 
hyperbaric oxygen especially if they continue with physical therapy. This 
also occurs in patients with chronic ischemie stroke and may have not seen 
any improvement in their conditions for years after their stroke even with the 
use of any and all other therapies. (Davis 1994) refers to this as an 
indication that the brain' s milieu intérieur in such cases are altered for the 
better since the neurons are able to slowly re-establish their lost connections 
in ways not possible before hyperbaric oxygen. 
Comparative functional volume obtained by single photon emission 
computerized tomography (SPEcn often indicates a large region of 
recoverable tissue. This functional volume of the infarct size can be 
demonstrated to decrease after one to several hyperbaric oxygen treatments 
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(Neubauer, 1990, 1992). The increase in blood flow to the area ofinfarction 
that occurs as a result of hyperbaric oxygen can serve as a clinical test to 
determine if there are salvageable neurons stili present in the penumbra. 
Presumably, if the test (SPECT first, then HBO then repeat SPECT) is 
positive, the person should receive benefit from the use of a series of 
hyperbaric oxygen treatments because of the revitalization of the ischemie 
penumbral tissues. 
Following acute, localized lesions of the central nervous system, arising 
from any cause, there are immediate depressions of neuronal synaptic 
functions in other areas of the central nervous system remote from the lesion. 
These remote effects result from "de-afferentation", a phenomenon known 
as "diaschisis"(Neubauer, 1990). 
After an interval of time, which will vary directly with the severity of the 
lesion, functional recovery may occur to some degree due to synaptic 
reactivation of neurons. This is favorably influenced by rehabilitation. 
Diaschisis most commonly manifests itself by such neurological signs as 
impaired consciousness or cognitive impairments including dementia, 
dyspraxia, dystaxia, dysphasia, incoordination and sensory neglect. The 
nature of diaschisis has been demonstrated by widespread depressions of 
local cerebral blood flow and metabolism extending far beyond the 
anatomical lesion. Neubauer pointed out that development of diaschisis is 
enhanced by latent circulatory disorders in both the affected and unaffected 
areas of the brain. Recovery of function is associated with recovery of local 
perfusion and metabolism (Neubauer, 1990). 
Thus if functionless ischemie penumbral tissue can be "re-activated" and be 
made to function again, a corresponding amount of the areas of diaschisis 
will be retumed to normal with normal blood flow and function retuming. 
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Personal experience gained ftom observing a patient Mr. F .Ch. indicated 
vast improvements. Mr. F. Ch. underwent 22 sessions ofhyperbaric oxygen 
therapy in a multiplaced hyperbaric oxygen chamber. His :first session took 
place on the third day after his :first stroke symptoms. We closely observed 
the development ofhis health status. It showed a striking reduction in 
spasticity, possibly due to improved function of neurons in the affected areas 
ofthe brain and increase ofP02 in the spastic, inactive and hypoxie muscle. 
ln addition, clinically, we observed the retum to life ofpreviously paralyzed 
and useless limbs, improvement in swallowing, speech, thinking (cognition) 
and memory. We also observed great improvements in his mood and in his 
motivation. There was an overall improvement in his motor as well as 
psychological functions. 
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RESULTS 
In this review, we sought to analyze the effect of HBOT in acute 
ischemie stroke by answering tb.e question: tb.e overall benefits regarding 
hyperbaric oxygen therapy after acute ischemie stroke. 
Which part does HBOT play in tb.e regeneration of damaged tissues after 
acute ischemie stroke? 
The ischemie penumbra does not receiving enough blood flow. As a 
result, the tissues in tb.is area do not get enough oxygen to function but 
do receive enough to stay alive. They are side to be, "sleeping neurons". 
These neurons are non-functional but anatomically intact and can be 
revived. In tb.e acute phase of stroke, damaged, dying and dead brain 
cells develop leaky plasma membranes allowing calcium and sodium into 
these cells which is followed by the accumulation of water which 
produces extensive and damaging edema. This swelling, if severe, may 
kill the person within tb.e first 24 to 72 hours. If tb.e person does not die, 
it may take up to 9 to 12 months for the edema to resolve during which 
time tb.e swelling compresses the involved brain blood vessels, limiting 
the flow of blood to the damaged tissues. As the swelling goes away, 
some of the blood vessels will regain their original diameters and normal 
blood flow will resume but other vessels will remain permanently 
narrowed, spastic or obliterated. HBOT has been shown to be effective at 
reducing tb.e amount of edematous tissue of tb.e brain significantly (see 
section on HBOn. The outermost portions of tb.e ischemie penumbra 
(those portions closest to normal brain tissue) are able to metabolize but 
at a reduced rate compared to normal tissues; however, tb.ey are receiving 
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more blood and oxygen than the centrally located ischemie tissues. 
Adeno-sine, a metabolite of ATP, is released from ischemie core, when 
cells metabolise and repair. Adeno-sine is a vasodilator that stim.ulates 
new capillaries to grow into the ischemie penumbra (neovascularization). 
During the :6rst year after a stroke, new blood vessels have been shown 
to be stimulated to move into the ischemie penumbra to re-supply it with 
a new blood supply (Anderson DC, Bottini AG, Jagiella WM, et al. , 
1991). 
Hyperbaric oxygen works to improve acute as well as chronic stroke 
patients by regenerating, repairing and generating new blood vessels to 
the injured parts of the brain. In the ischemie penumbra, the blood 
vessels are often constricted to the point that red blood cells cannot pass 
through them. This creates the situation where only plasma is able to pass 
slowly to part or most of the ischemie area. Since plasma has nutrients, 
the tissues of the ischemie penumbra are able to remain alive by using 
anaerobic glycolysis (metabolism without oxygen) also known as 
fermentation. Anaerobic glycolysis only produces 2 moles of ATP per 
mole of glucose metabolized instead of the 36 moles of ATP formed 
when oxygen is present. Thus the tissues suffer from a chronic shortage 
of ATP and its sub~nt metabolite, adenosine. 
Hyperbaric oxygen forces oxygen into the plasma to such a degree that as 
the plasma passes into the ischemie penumbra, the ischemie tissue begins 
to receive enough oxygen for aerobic glycolysis (metabolism that uses 
oxygen) to occur once more. This creates a surge of ATP production in 
the ischemie tissue which continues to be produced as long as the patient 
is within the hyperbaric oxygen chamber. When a patient is taken out of 
the chamber, blood oxygen and tissue oxygen levels fall back to pre-
treatment levels of oxygen within 4 hours. As the tissue oxygen level 
falls, the newly generated ATP is used by the ischemie tissues and 
adenosine is released into the surrounding tissues in an effort by the 
tissues to continue receiving oxygen. As a part of this survival 
mechanism, adenosine and other chemical mediators are released into the 
surrounding tissues stimulating neovascularization. Done daily over 
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many days, the HBO stim.ulates new blood vessels to grow into the 
ischemie tissues retuming them back to normal in terms of their oxygen 
supply. Recovery of function is associated with recovery of local 
perfusion and metabolism 
What is the relationship between HBOT and synaptogenasis in patients 
after stroke? 
The rationale of use of Hyperbaric Oxygen in neurological indications is 
based on the finding in SPECT studies that around the central area of 
neuronal death is the penumbra: peri-infarct zone having idling or 
sleeping neurons and gliosis ( dead neurons) on CT scans may actually be 
viable tissue for years following the insult. HBO delivers high Oxygen to 
these "sleeping cells" and reactivates them. 
This is achieved by reducing cerebral edema, reverses the reduced 
flexibility of erytbrocytes and improves the function of neurons rendered 
inactive by ischemialhypoxia. The improvement of brain function is 
reflected by the improved electrical activity of the brain." 
Once the ischemie penumbral tissues are no longer suffering from a lack 
of oxygen, they are able to begin to repair their injured neurons, glial 
cells and extracellular matrix. These neurons repair their cell bodies, 
dendrites, axons and synapses. They also grow out and extend to the 
many lost connections that occurred at the time of the stroke. Due to 
these events, patients experience positive results during the 60 days of 
daily hyperbaric oxygen because of the renewed oxygen supply 
(neovascularization). In addition, most patients continue to see 
improvements for another six or more month after the completion of the 
course of hyperbaric oxygen due to continuing cellular repair and 
reconnections. 
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In which way does HBOT work to improve spasticity (a muscle disorder 
common in patients after stroke )? 
Myelin sheaths cover many nerve fibers in the central and peripheral 
nervous system; they accelerate axonal transmission of neural impulses. 
Disorders that affect myelin interrupt nerve transmission. 
Demyelination is often secondary to ischemie disorders, which can be 
segmental or patchy, affecting multiple areas simultaneously or 
sequentially. Extensive myelin loss is usually followed by axonal 
degeneration and often cell body degeneration; both may be irreversible. 
Spasticity may be dueto the following: 
~ Decreased function of neurons in affected areas or brain 
~ Decreased PO 2 in hypoxie and inactive muscles 
Remyelination often occurs with repair, regeneration and complete 
recovery of neural function. 
The possible mechanism of action offered by HBOT in neurological 
disorders is the relief of hypoxia, improved microcirculation and 
cerebral metabolism, reduced cerebral edema by vasoconstrictive effect, 
increased permeability of the blood-brain barrier and preservation of 
partially damaged tissue and prevention of further progression of 
secondary effects of cerebrallesions. 
The hyperbaric oxygen induced blood vessel repair results in a 
permanent structural change in the blood vessels that re-supply the 
previously darnaged and nonfunctioning nerve tissue which was 
occuning due to diminished and inadequate blood flow. These new blood 
vessels improve the blood flow and oxygen delivery to the damaged 
brain tissues. Due to an increase in oxygen delivery, damaged brain 
tissues are able to initiate reparation processers to their injured neurons, 
glial cells and extracellular matrix. Reparation of neural cell bodies, 
dentrites, axons, synapses as well as remyelinations occurs. This results 
in permanent improvements of neuron function. 
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The reported rate of improvement is 400/o to 100%. It shows a striking 
reduction in spasticity possibly due to improved fu.nction of neurons in 
affected areas or the brain and secondly to rise of P02 in the spastic 
inactive and hypoxie muscle. In addition clinically, what you see is the 
retum to life of a previously paralyzed and useless limb or limbs, 
improvement in swallowing, speech, thinking (cognition), memory, etc. 
Quite obviously not all of the disabilities disappear since there was a 
central core of dead tissue that cannot be revived. 
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CONCLUSIONS 
-- - --- - ----- """-==================="""" 
The present work shows the fundamentals of the use of HBOT in general. 
Davis (1994) in his work managed to show that literature and clinical 
experience predict that between 80% - 90% of stroke patients will 
positive1y benefit from HBOT. This is dueto its beneficial effect. Some 
of this beneficial effects are, increase in oxygen delivery, decrease in 
cerebral edema, decreased lipid peroxidation, inhibition of leukocyte 
activation, maintenance of blood-brain barrier integrity as well as the 
reduction in the volume of brain infarction. HBOT is clearly not only 
useful for patients after acute ischemie stroke, but also for a variety of 
conditions indicated by UHMS (Undersea and Hyperbaric Medical 
Society, 1999). 
This information is vítal firstly because health care practitioners have 
tried a variety of different methods to improve the quality of daily life for 
post-stroke patients but the overall results where unsatisfactory. 
Although stroke is a leading cause of death and disability, its 1ong term 
management is often marked by feelings of hopelessness on the part of 
both patients and professionals. Any treatment that provides increased 
functional abilities and helps these people live more independently and 
economically should be made available as soon as possible, for both 
humanitarian and economic reasons. Secondly because physiotherapy is 
a fast growing part of the medical field, in which more and more 
therapist are becoming independent This independence requires accurate 
and effective decision-making skill, concerning patient care and 
management. In order to achieve these skills, it is impemtive to consider 
the importance ofunderstanding fundamentals, mechanisms of action and 
the effects of adjuvant therapies such us HBOT. Lastly, when 
considering clinical application of HBOT, potential bene:fits must be 
balanced against the potential toxicity. Hence, this work presents not 
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only the considered beneficial e:ffects ofHBOT; it also shows the adverse 
e:ffects that may occur dueto HBOT. 
The reported rate of improvement is 40% - 100% wbich is much greater 
than the natural rate of recovery. In a number ofboth animal and hwnan 
studies, hyperbaric oxygen has been shown to diminish cerebral blood 
flow from 1 to 29% (average 14.7%), wbich some people have claimed 
to be detrimental to a stroke or brain injured patient. All of these studies 
were done in normal non-brain injured subjects while the studies that 
were done in brain injured patients all showed an increase in cerebral 
blood flow (Jain, 1996 page 239). 
Dr. K.K. Jain states that, "Vasoconstriction and reduced cerebral blood 
flow do not produce any clinically observable effects in a healthy adult 
when pressures of 1.5 to 2 ATA are used. The e:ffects of HBO are more 
pronounced in hypoxie/ischemie states of the brain. HBOT reduces 
cerebral edema and improves the function of neurons rendered inactive 
by ischemia/hypoxia. The improvement of brain function is reflected by 
the improved electrical activity of the brain." 
With this fundamental knowledge at hand, it is possible to continue from 
this cellular level to the next level. Evidence from well-conducted 
clinical studies is limited. Future work on this topic should aim to answer 
the arising question such as: 
+ The number ofHBOT sessions recommented, before engaging 
physiothery as part of a complex healing intervention to patient 
after stoke? 
A lack of agreement on the dosage of HBOT and duration of treatment 
was identified. Clear information on the dosage and duration of HBOT 
could be in an important research question to answer. 
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i 
Comparison of Types of Hyperbaric Oxygen Therapy 
Chambers 
! Advantages Disadvantages 
I 
1 Monoplaced chambers 
I 
[ Relatively low purchase 
I I 
Patient isolated during 
treatment 
I 
1 price 
I 
j Requires little space and 
I relatively minor facility 
I renovations 
! Modest program 
I 
: capitalization 
I 
1 Treatm.ent protocol 
[ specific to patient and/or 
j condition 
I 
1 Modest staffing 
i requirements 
I 
I 
Patient does not wear 
1 mask/hoodlhead tent for 
I 
i oxygen delivery 
I i Relatively mobile chamber 
l 
[ for possible relocation 
I 
' I No risk ofiatrogenic 
j decompression sickness in 
I • staff 
1 patientor 
I 
; Add-on capability for ease 
of program expansion 
' I 
i Inability to suction patient 
Limited pressure capability 
I (3ATA*) 
i Pure oxygen environment; 
I I associated :fire hazard 
Inability to use certain 
diagnostic and/or 
therapeutic equipment 
(transcutaneous oxygen 
assessment now available 
[ radiometer -
transcutaneous monitor -3]) 
i 
I Increased risk of 
j complications from 
I pneumothorax and/or 
I I tension pneumothorax and 
I arterial air embolism 
[ developing during 
j decompression 
- j 
Multiplaced chambers I Greater working pressure : Higher capitalization 
I Constant patient 
attendance 
Ability to use a variety of 
electrically generated 
-----------·--- _____ I-----
I requirements 
Major space requirements; 
j basement and/or ground 
tloor levellimitations 
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I signals during therapy 
Attendants able to enter 
~ and exit during therapy 
Ability to manage 
complications such as 
pneumothorax without 
I releasing pressure 
Ability to conduct 
intensive care activities 
during treatment 
Higher operating costs 
Larger and experienced 
staffing requirements 
Risk of decompression 
sickness in interna! 
personnel 
I All patients on same 
I protocol 
I 
Uncertain oxygen delivery 
tension at patient with face 
mask 
Severe maxillofacial andlor 
head and neck involvement 
possibly making e:ffective 
delivery of oxygen difficult 
I Facility fire-associated 
decompression 
! requirements 
I Significant equipment, 
I maintenance and system 
I upkeep requirements 
- ·- ~ - -
TABLE 4 COMPERISON OF HBOT CHAMBERS (D.STEENBLOCK, 1998) 
* ATA = atmosphere absolute 
Primary Effects of Hyperbaric Oxygen 
r··-·-- ·- ---· ·----- - --·-r . -·-
Mecbanism i Effect 
i i ,-·- . --- -r- -- -----· ·-···-·-·-
~ Hyperoxygenation Greater oxygen carrying capacity 
! 
i Increased oxygen diffusion in 
tissue fluid 
Diffusion distance proportional 
1 Clinical Utility 
I 
Severe blood loss anemia 
(unable to carry oxygen) 
! Crush injury, 
. compartment syndrome 
i 
i graft, and tlap salvage 
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,-····- . .. ... ·- .. - --- ----- -·- ---· 
! to the square root of dissolved ~ ( decreased perfusion) 
I 
I Edema (increased 
I I oxygen 
I 
I 
I I 
I diffusion banier) 
I , --- ---··-··----,---· ··· 
Decrease gas bubble ; Boyle law - Gas volume 
I 
size j inversely proportional to 
I 
I presH smebari diffus" gradi I yper c Ion ent 
favors gas leaving the bubble 
and oxygen moving in, 
metabolizing oxygen in the 
i bubble 
Law ofLa Place p-4t/r 
I 
Bubbles unstable as they 
1 
decrease in size 
I 
Decompression sickness 
Air embolus syndrome 
- ··-. ·- . 
TABLE s Primary Effects of Hyperbaric Oxygen (JAIN KK, 1990) 
Secondary Effects of Hyperbaric Medicine 
1 Mechanism 
V asoconstriction 
Angiogenesis 
EtJect 
....... - --- ·- ----
Decreased inflow into tissues 
Decreased edema 
1 Increased oxygen gradient 
i between wound and surrounding 
environment 
Clinical 
Application 
; Crush injuries 
/ Acute burns 
I Compartment 
syndrome 
I 
-•8'••••· -- - - ... 
I i Graft and tlap 
Í salvage 
I 
\ 
i Osteoradionecrosis 
1431 Pa g e 
·--- -·· ·--·---·-··-
Fibroblast proliferation 
1 
Leukocyte oxidative 
1 killing 
I 
: Toxin inhibition 
Antibiotic synergy 
I lncreased fibroblast proliferation 
1 leading to increased collagen 
deposition and increased 
fibronectin, which aids in 
1 
neovasc~on 
I 
iRadiation 
i i endarteritis 
! obliterans 
! 
I Chronic wounds 
···-----·-- r--- ---· 
Oxygen-dependent proliferation Chronic wounds 
I 
-r·--·-- -- ---
I Increased oxygen free radicals 
I Anaerobes lack superoxide 
1 dismutase to control oxygen free 
: radicals 
I 
I 
Radiation-induced 
in jury 
·- ··· - --
[ Necrotizing soft-
l tissue infections 
Chronic 
osteomyelitis 
······ - ·~ ·--··----··---
' I Decreased clostridial alpha toxins ! Clostridial gas 
! 
I 
I 
I 
--~;--·-··-·-- --
1 Fluoroquinolones, amphotericin 
I 
I
, B, and aminoglycosides - Use 
I oxygen to transport across cell 
1 membranes 
gangrene 
I Decreased cardio 
toxins 
I Sepsis 
I 
Necrotizing 
infections 
·- . . 
Tahle 6 Secondary Effects OfHyperbaric Medicine (JAIN KK, 1990) 
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- -I 
Signs and Symptoms of Oxygen Toxicity 
--- ----·- .----------- ... --·---- -----
1 
; CNS 
I 
; Nausea and vomiting 
í 
: Seizures 
-r· . -. . -- -·- ---- -- --- -- ---·- -
j Pulmonacy 
·r---
. Drycough 
I 
I 
- -l . --·-··· ______ ..., __ _ 
I Substernal cbest pain 
-· --r---- ---------------. ------- ---·· 
: Sweating ; Bronchitis 
I 
I 
--- -- -- ·r-·· ·---
; Pallor j Shortness ofbreath 
! Muscle twitching --~ ~onary edema 
J Anxiety and/or respiratory changes Pulmonary fibrosis 
I 
Visual changes 
I -
· Tinnitus 
Hallucinations 
Vertigo 
Hiccups 
Decreased level of consciousness 
Tahle 7 Signs And Symptoms Of Oxygen Toxicity (JAIN K, 1999) 
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I 
i 
-: 
I 
--, 
Treatment Protocol Guidelines 
' Dosage 
! 
: 
·-··· -··-····-- ····--l--· --- ··- -
i Indieations 
! 
1 2.0ATA*oxygen X 90min 
...... .. -l Wound healing 
i ! Compromised skin grafts andlor flaps 
i Thermal burns 
i o li. i steomye tis 
! Crush injury andlor compartment syndrome 
Mucormycosis 
: 2.0 ATA oxygen X 90 min with Wound healing 
10 min air break (high seizure 1[ Compromised skin graft andlor flaps 
risk) Thermal burns 
Osteomyelitis 
2.5 ATA oxygenX 90 min 
I Crush injury andlor compartment syndrome 
Mucormycosis 
; I Nonclostridial gas gangrene 
I Necrotizing infections 
Osteomyelitis (Escherichia coli or Pseudomonas 
species isolated) 
J Late radiation tissue injury (osteoradionecrosis, 
I soft tissue radionecrosis) 
-- -·-· ··--r---- ··--
3.0 ATA oxygen X 90 min i Carbon monoxide poisoning 
i 
· Clostridial gas gangrene 
TABLE 8 TREATMENT PROTOCOL GUIDELINES (JAIN K, 1999) 
*ATA = atmosphere absolute 
1461 Pa g e 
Good 
Mkroglia Growth and trophic factors 
production ( e.g. transform.ing 
growth factor B-1) 
Oxygen free radical scavenging 
Phagocytosis of dead cellsldebris 
Attraction of astrocytes involved in 
repair processes 
Degradation of e:xtracellular matrix 
during remodeling 
Bad 
Production of pro-intlammatory 
mediators and cytotoxins ( e.g. 
interleukin -lB, matrix 
metalloproteinases) 
Disruption of the blood-brain 
barrier 
Tahle 9 Janus/Faced Contribution Of Glieal Cells To Stroke Pathophysiology 
(DIRNAGL U, SIMON RP, HALLENBECK 1M, 2003) 
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